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The sustainability pressures faced by the health systems today will not be the same in the 
future. To ensure the long-term viability of Universal Health Care provision, agile solutions 
are being designed to navigate the dynamic problem of optimising health under constraints. 
Within the UK, population health management is being researched and applied. Impactibility 
modelling is a new development in this area which seeks the greatest increase in population 
health, patient experience, and reduction in health inequalities for the cost incurred.  
It is important to develop and apply impactibility modelling as an agile solution, so that it may 
be successful in accommodating the changing nature of the optimisation problem. This 
dissertation provides insights in that direction at this early stage of IM development. 
A literature review is conducted to understand the development of impactibility modelling so 
far and create practical recommendations for its development and application in the UK. 
These recommendations are distilled into an ethos of IM including awareness, clarity, 
collaboration, preparedness and working across a wider health system. 
A proof of concept model shows how some of these recommendations can be applied in 
practice, namely clarity and awareness. Through a case study of Type 2 Diabetes Mellitus, 









There are pressures on the National Health Services (‘NHS’) in the UK which mean it may 
not always be available to us as it is today. These pressures drive people to seek creative 
solutions that improve health, make patients more satisfied, reduce health inequalities in 
society and try to lower the costs of doing so. Impactibility modelling is a new idea for a 
creative solution that will try to direct NHS resources in an effective and efficient way to help 
navigate those pressures so the NHS can continue well into the future.  
This dissertation provides a summary of what has been thought about so far on this idea. It 
also makes recommendations to those working to develop this new idea further. An example 
of how some of these recommendations could be carried out in practice is provided. This 
example looks at health data to try to understand why some people with Type 2 Diabetes are 
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Chapter 1 Introduction 
Universal Healthcare Coverage is established or is being established in many countries to 
protect people from the hardships of poor health and ensure long-term economic 
development (3). Health systems that deliver Universal Healthcare Coverage take many 
forms globally. In the United Kingdom (‘UK’), the National Health System (‘NHS’) was 
established in 1948 to deliver society wide affordable medical treatment and has continued 
to be predominately publicly funded (4). The systems in Western societies, including the 
NHS, are experiencing increasing demands to deliver services and at the same time, the 
ability to supply services is increasingly challenging. These pressures create sustainability 
concerns for health systems and without change the problem is expected to worsen (4, 5). 
This has motivated efforts to reimagine health systems by adopting an ‘Integrated Care’ 
approach that aims to deliver health services more holistically (4); increasing the ability of the 
health system to supply care more efficiently (4, 6-8). Now attention has turned to Population 
Health Management to deliver further improvements in health system sustainability by 
reducing the demand for care. Population health management seeks improvement in 
population health status and patient experience, while reducing health inequalities and the 
associated costs. This approach shifts attention from simply delivering care to preventing the 
requirement for care in the first place, as seen in public health. It does so by targeting 
intervention on those at risk of adverse health events.  
It may be possible to improve the results of targeted interventions further by using 
Impactibility Modelling. This requires identifying those in a population most likely to be 
impacted positively by a particular intervention. This approach has potential to further 
improve health system sustainability. 
This dissertation explores Impactibility Modelling and its potential contribution to Population 
Health Management. A literature review summarises the current state of Impactibility 
Modelling development. Recommendations for the development and application of 
Impactibility Modelling in practice follow. A proof of concept model illustrates how 
recommendations could be applied in practice and explores the usefulness of multi-state 
models to assess impactibility. Through these recommendations and proof of concept, this 
dissertation provides direction forward in the next steps of IM development at a time when it 
is just being created. 
This dissertation has nine chapters. Chapter 2 provides background information, the 
structure used to review the literature and the aims of the dissertation. Chapter 2 to Chapter 
3 cover the literature review, providing a wider appreciation of Impactibility Modelling and 
Impactibility modelling 
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conclude with recommendations. Chapter 4 to Chapter 7 cover the proof of concept, showing 
how the recommendations of clarity and awareness could be applied in practice and 
explores the usefulness of multi-state modelling. Chapter 8 discusses how this proof of 
concept contributes to the development of Impactibility Modelling and Chapter 9 concludes. 
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Chapter 2 Background 
Shortly after the creation of the NHS there were sustainability pressures which saw 
adaptations to how the health system operated including the privatisation of dental and 
optical services (9). Today sustainability pressures to systems that contribute to health are 
present in varying nature across the world. Western health and social care systems, 
including the NHS in the UK, face demand-side pressures from demographic and 
epidemiological causes, including population ageing, obesity trends and increased 
prevalence of chronic disease (4, 5, 10, 11). In addition, supply-side political and financial 
pressures occur, including increasing public and patient expectations, medical advances, 
human resource skills shortages and reduced budgets (4, 5, 10, 11). These pressures are 
the problems now but may not be the problems faced in the future. In general, the problem is 
one of optimisation; to optimise health under constraints. 
To match the dynamic nature of the problem, an agile solution is required. The following 
sections provide, in general terms, a way to view the problem and frame the solution. This 
provides an appreciation of the wider context for Impactibility Modelling (‘IM’) that influence 
its objectives. The application of agile solutions in the UK is discussed and the motivation 
behind IM as a topic. 
2.1 A dynamic problem: To optimise health under 
constraints 
Optimising health under constraints can be viewed within the health and social care system 
and within a wider system that determines health. 
2.1.1 Within the health and social care system 
When an individual requires an intervention and is within the health or social care system, 
the Universal Healthcare Coverage (‘UHC’) Cube (3) and Institute of Medicine’s 6 quality of 
care domains (12) are frameworks for optimisation problems in health. 
The objective of the UHC Cube is to increase health coverage by increasing the number in 
society covered, increase the services offered and reduce the costs borne by the user, as 
shown in Figure 1. 
Impactibility modelling 
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Figure 1: WHO UHC Cube 
 
Sourced from World Health Organisation (3)(p.13) 
The dimensions of the cube could be maximised by spending more however, with limited 
health-economy resources, this is not feasible in the short-term. Alternatively, the 
dimensions could be maximised by diluting quality. Quality in delivering health services is 
key and can be considered in 6 domains, care ought to be: safe, effective, patient-centred, 
timely, efficient and equitable (12). To retain quality under resource constraints is a 
continuous challenge which requires ongoing monitoring and evaluation(13). 
2.1.2 Within a wider health system 
Before individuals need care, multiple systems work to maintain and improve health. This 
wider system that determines health is also where causes of ill-health mostly lie (14). This 
wider health system (see Key Term 1) is relevant to public health and examples of wider 
determinants of health are shown in Figure 2 (15). 
Key Term 1: Wider health system 
 
• the system that determines health outwith 
the health and social care system
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Figure 2: Dhalgren and Whitehead rainbow model 
 
Image sourced from Public Health England (15) 
The Institute for Healthcare Improvement‘s Triple Aim refers to the simultaneous objective of 
“improving patient experience (including quality and satisfaction)[,] improving the health of 
populations[,]..and reducing the per capita cost of achieving health”(14), as shown in Figure 
3. This framework can be used to view the optimisation problem across both the health and 
social care system and the wider health system (13, 14, 16). In the UK, a fourth aim of 
reducing health inequalities has been adopted (10). 
Figure 3: The IHI Triple Aim 
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2.2 An agile solution: A control cycle 
The nature of the optimisation problem varies by local context, over time and with the 
population. The solution must therefore adapt, requiring ongoing tailoring to suit both the 
local health and care system and the wider health system.  
A control cycle is a generic systematic framework to develop an agile solution within (18). 
The process is cyclical and involves analysing the problem, developing and implementing a 
solution, then monitoring it (19), as shown in Figure 4, before starting again. 
Figure 4: A control cycle 
 
Based on control cycle frameworks from Moen (18) 
This framework is well suited to dynamic problems such as optimising health under 
constraints and where a solution is not yet known but can be developed iteratively based on 
learnings from the process. 
2.2.1 Population health management 
PHM is a growing area of research and practice that seeks better health outcomes and 
distribution of outcomes using a control cycle (20). PHM seeks to “estimate[e]..the cross-
sectoral cost-effectiveness of different types and combinations of investments for producing 
health” (21)(p.381). It seeks to optimise health as delivered across both the health and social 
care system and the wider health system (13).  
PHM is a wide field as shown in Figure 5. Fundamental to PHM is data analysis which aims 
to better understand individual and population need (public health) in order to better meet 
  Impactibility modelling 
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those needs (10, 13). This understanding allows for a targeted approach to the delivery of 
upstream and downstream interventions1 (10, 13). 
Figure 5: Dimensions of Population Health Management 
 
Sourced from the Good Governance Institute Development and Research Report (10) (p.9) 
The Triple Aim has been adopted as optimisation criteria when designing PHM solutions to 
optimise population health under constraints (4, 8, 10, 13, 22-27). Herein, the UK quadruple 
aim will be referred to as the PHM aims (see Key Term 2). 
Key Term 2: Population health management aims 
 
PHM systems seek to analyse population need and intervene accordingly, with the 




1 Upstream and downstream are used in this context to describe interventions to treat 
disease and interventions to treat the causes of disease. 
2 I have visually represented, in Figure 6, the PHM system under the control cycle process in 
Figure 4. 
•improving patient experience (including 
quality and satisfaction)
•improving the health of the population
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Figure 6: Analysis, action and monitor stages of Population Health Management 
 
2.2.2 Learning health systems 
When a control cycle is applied in a health system context it is known as a Learning Health 
System (‘LHS’). PHM population analysis is an example of analysis in an LHS (28). 
However, an LHS is not just analysis; it is a sociotechnical concept seen when: 
science, informatics, incentives, and culture are aligned for 
continuous improvement and innovation, with best practices 
seamlessly embedded in the delivery process and new knowledge 
captured as an integral by-product of the delivery experience (29) 
Under this control cycle, health systems develop iteratively and are responsive to the 
dynamic nature of the optimisation problem (30). With each complete cycle, the health 
system learns and continuously improves to better optimise health under constraints (28, 
31). 
In many countries, including the UK, the emphasis is moving away from “health systems 
designed to better manage chronic disease care towards systems designed to enhance 
population health” (10)(p.8). That is, moving away from solutions designed for today’s 
problems to agile solutions that can adapt to the changing nature of the optimisation problem 
including PHM and LHS (16, 24). 
2.3 UK application 
The NHS model of acute episode healthcare delivery is seen as unsustainable by 
policymakers (10). A new model of integrated care allows for “locally appropriate proposals 
to improve health and care for residents”(6) providing a more seamless service to patients 
and investment in downstream and upstream prevention (4). 
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The NHS’s journey toward this integrated model is progressing with Sustainability and 
Transformation Partnerships (‘STP’s) due to be replaced by Integrated Care Systems (‘ICS’) 
by April 2021(10). These collaborations between local NHS organisations and councils, to 
improve population health, plan the long-term needs of the local community (6) and take 
“collective responsibility for managing resources”(6). That is, optimising health under 
constraints across the health and social care system and the wider health system.  
To further this journey, PHM is being researched and applied in the UK (8, 24, 32-35).  
2.3.1 Application of Actuarial sciences 
Actuarial sciences can help develop agile solutions using statistical analysis and data 
science to understand dynamic problems of health risks at an individual and population level 
along with resource allocation. In the United States of America (‘US’), actuarial sciences are 
applied (19, 23, 36-40) and PHM case studies have passed the initial development phase 
(10, 41). 
An interest in progressing PHM in the UK, and in applying actuarial sciences, has led to the 
creation of a working party. The PHM Working Party, established in 2018 by the Institute and 
Faculty of Actuaries, is a member-led working party including actuaries and NHS England 
professionals3 (11). The working party’s initial focus is on the next development in PHM, 
namely IM. 
2.4 Impactibility Modelling 
‘Impactibility4 model’ was coined by Geraint Lewis (25), Chief Data Officer at NHS England 
(42). A working definition was established in 2019 by the working party in collaboration with 





3 More details on the Working Party including membership is provided in Appendix 2. 
4 There is debate over if the term should be spelt ‘impactibility’ or ‘impactability’ however, 
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Key Term 3: Impactibility 
 
Sourced from PHM working party (43) 
2.5 Dissertation aims 
This dissertation will explore IM as a new development to PHM and provides direction 
forward in that development through a literature review and proof of concept.  
A literature review summarises the current state of IM’s development. This is followed by 
practical recommendations for IM’s development and application in the UK as part of the 
agile solution required to suit the dynamic problem of optimising health under constraints.  
A proof of concept model illustrates how recommendations could be applied in practice and 
establish the usefulness of multi-state modelling for IM.  
•is the degree to which different sub-populations
will benefit from a range of interventions and using
this information to tailor appropriate interventions
within agreed boundaries for the 'value' gained
from resources spent.
Impactibility
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Chapter 3 Literature Search 
3.1 Aims and objective of literature search 
An agile solution can accommodate the dynamic problem of optimising health under 
constraints. Exploring IM as an agile solution may better allow for the structural changes 
considered necessary for the sustainability of the UK health system (4, 5).  
To effectively explore IM, this literature search aims to: 
• establish clarity in the objective of IM; and 
• clearly establishes how IM fits within the control cycle framework.  
The objective of this literature search is to summarise the current state of IM development 
and to create recommendations for the development and application of IM in practice. This 
has not yet been provided in the literature and is considered useful at this time when IM is 
just being created. 
3.2 Search strategy 
IM a relatively new development so a pragmatic approach has been taken to locate recent 
and relevant sources limited to those concerning ‘impactibility’.  
A forward and backward citation search was undertaken from the working party seed papers 
on IM (25, 44). All references in these papers were checked for relevance in the backward 
citation search. A forward citation search captured current literature using Google Scholar to 
source citations of the seed papers as of 1 June 2019.  
The term “impactibility” was searched using Google Scholar5 on 1 June 2019 with publication 
years limited 2010 to 2019 to ensure all literature since Lewis’ paper (25) was captured.  
To broaden the search, materials using alternative terminology for the concept of 
impactibility were considered. This was not exhaustive but allowed for a wider contextual 
understanding of impactibility as a concept. Topics concerned with optimising health under 
resource constraints seemed appropriate, including priority setting and rationing (45), triage 
and case-finding(46), and precision medicine(47)6. 
 
 
5 Medline, Embase, Web of Science, and Scopus were search but Google Scholar was the 
most fruitful. 
6 More detail is provided in Appendix 4 
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3.3 Search summary and process 
A representation of the literature search is provided in Figure 7.  
Figure 7: Flow diagram of literature search 
 
Image created using online tool Theta (48) 
Literature was located, citations imported to EndNote, deduplicated and exported to Excel. 
After a review of the title and abstract, seemingly relevant papers were progressed to a full-
text review and marked as either not relevant, low, medium or high as shown in Table 1.  
Table 1: Relevance grading 
Frist review: Title and abstract Second review: Full body text 
Grey – not progressed Low – background information 
37 sources 
Amber – full paper review required Medium – related to the wider context 
26 sources 
Green – appears to be relevant High – directly related to ‘impactibility’ or IM 
19 sources 
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Chapter 4 Literature Review 
IM is part of population analysis, but in a control cycle it interacts with the intervention and 
the achievement of PHM aims assessed in the evaluation. All elements of PHM are therefore 
relevant. This review is presented using the control cycle framework presented in Chapter 2. 
The PHM system is portrayed formulaically in Section 4.1. In Section 4.2 - 4.4, each element 
of the PHM system in Figure 8, is populated with a summary of the relevant literature. 
Section 4.5 summarises the literature relevant when designing IM within an LHS. 
Recommendations for the development and application of IM in practice are distilled into an 
ethos of IM which is presented to conclude. 
4.1 Formulaic view of Population Health Management 
PHM can be considered formulaically, as shown in Figure 87. A population is analysed, 
provided with an appropriate intervention, and the cumulative effect evaluated against its 
ability to meet the PHM aims.  





7 I have visually represented the PHM system under each element of the control cycle; 
analysis, action, and monitor. 
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There appear to be two possible approaches to PHM systems (49-51), referred to herein as 
approach A and B, represented in Figure 98. 
Population analysis can be used for patient selection to put forward people at-risk of an 
outcome, for which the intervention is intended, and for whom it is anticipated to benefit. 
Here the intervention does not change. A short-term return on investment (‘ROI’) is sought 
by directing selected patients to generate ‘value’ from resources that have been allocated. 
Patient selection is sometimes referred to as ‘case-finding’ (16, 25, 26, 50, 52-54). The 
literature mainly adopts approach A, where the intervention is held static (49). 
Figure 9: Two approaches to Population Health Management 
 
Population analysis can be undertaken to understand who is at risk of an outcome and to 
find which intervention would benefit that sub-population (22). Where the intervention 
changes to suit a given population, it is akin to precision medicine (47) which embraces the 
heterogeneity between individuals to find the most beneficial intervention (55).This approach 
is referred to as resource tailoring (49) or resource allocation (50). It seeks a long-term ROI 
by understanding population need and generating ‘value’ by allocating resources 
accordingly. There are fewer examples from the literature under approach B, where the 
intervention is dynamic (49). 
Patient selection seeks to find a patient for a fixed intervention. Resource tailoring seeks to 
find the most suitable intervention for an individual from a menu of choices. Resource 
 
 
8 I have visually represented the two approaches in Figure 9. The terminology of approach A 
and B is adopted as there was no clear alternative in the literature. 
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allocation seeks to set the menu of interventions available to suit the population, as shown in 
Figure 109.  
Figure 10: Patient selection, resource tailoring and resource allocation 
 
Approach A and B to PHM can align with the strategic objective of navigating away from the 
acute delivery of healthcare (a static solution) toward increasing population health through 
collaboration of wider health system actors (an agile solution). The role IM plays within a 
PHM system depends on the approach adopted; altering its objectives. Under approach A, 
impactibility criteria are chosen to allocate patients to an intervention. Under approach B, 
impactibility criteria are chosen to allocate suitable interventions to patients.  
4.2 Population analysis 
In a PHM system, data analytics are leveraged in population analysis (16) to understand and 
predict population need (10). This predictive modelling (‘PM’) provides insights that allow 
people at risk of adverse health outcomes and people that can benefit from an intervention, 
or not, to be considered by clinical practitioners before the event occurs (10, 16, 25). It 
facilitates the proactive provision of interventions (16, 24, 25, 27) to better manage the 
adverse health outcome risk and so better achieve the PHM aims (16, 24, 26, 33). 
PM under approach A for patient selection is similar to triage; it is an attempt to increase 
transparency and formalise practice for priority-setting while relying on clinical judgement 
(16, 46). Under approach B, PM allows population need to be understood and resources 
planned on forecast future need (49). It also allows policymakers to target and prioritise 
services specific to the local context (56) with increased transparency using insights gained 
from experience exhibited in local data (10). 
 
 
9 I have visually represented this in Figure 10 where the circles represent people, the 
squares interventions and the arrows represent the decision made. 
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In this setting, PM has two elements; risk stratification (‘RS’) and IM. RS highlights the 
people at risk of an outcome such that an appropriate intervention can be allocated (7, 24-
26, 49, 57). IM highlights which people may benefit from a given intervention under approach 
A or allows for improved resource tailoring and allocation to benefit people under approach B 
(25, 44, 49).  
4.2.1 Risk stratification 
The majority of PM so far has been RS which stratifies a population by the risk of an adverse 
health outcome based on historic data (11, 16, 22, 24, 25, 58, 59). Explanatory variables are 
established as risk factors for the event and these insights leveraged to find people 
susceptible to the event in the future (22, 25, 26). The objective of RS is to flag people at-risk 
to practitioners before an event occurs (7, 23, 25, 26, 49, 57, 59).  
There is a need for high quality electronic health record data that contains the outcome of 
interest and explanatory variables (41, 57). Linked primary, secondary and social care data 
sources are useful as more factors affecting an individual’s health can be appreciation and 
translated into action (16, 60). The data needs to be timely and of good quality to allow for 
appropriate actions to be taken (53). 
4.2.1.1 Explanatory variables 
Data items can be tested for statistically significant explanatory power over the outcome of 
interest (25, 59). Demographic, clinical and social explanatory factors are commonly used (7, 
61, 62) but the variables may be specific to the outcome, data, time period and population (7, 
63). 
Commentary on how the choice of explanatory variables contribute to or detract from the 
achievement of PHM aims is discussed only theoretically in the literature (22, 24). For 
example, given the Inverse Care Law (64) selecting Index of Multiple Deprivation (‘IMD’) may 
highlight high-risk patients in lower socio-economic areas. Combined with proactive 
intervention, this may improve health status and reducing health inequalities in a population 
(25). However, how this will be measured, why it was chosen and how it is assumed to meet 
the PHM aims is not explicit in the literature.  
4.2.1.2 Outcomes of interest  
Lewis suggests that the outcome of interest for the RS model should be “undesirable to the 
patient, significant to the health services, preventable, and recorded in routine administrative 
data”(57)(p.4). More generally, the outcome of interest could be any event such that the 
management of that event works towards the PHM aims. 
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Medical outcomes and patient behaviour are less common outcomes of interest in the RS 
literature (23). The most common is hospital admissions, especially preventable and 
unplanned admissions (24, 33, 44, 57, 61-63, 65-70). This outcome is chosen explicitly to 
reduce costs as hospitalisation is an expensive form of care (44, 65). Although “intuitive[, this 
is] a largely untested assumption”(8)(p.244) and the literature is silent on how this outcome 
contributes to the other PHM aims (65). 
IM is a new development to population analysis and learnings can be leveraged from RS 
experience so far.  There is a lack of clarity in the literature on why and how the choice of the 
outcome and explanatory variables achieve each of the PHM aim.  
4.2.2 Impactibility modelling 
IM goes beyond predicting who is at-risk, to provide insight on ‘impactibility’ i.e. “who will and 
who will not respond to preventive interventions”(10)(p.13). Literature specifically regarding 
IM primarily discusses the rationale and theoretical approaches.  
4.2.2.1 The rationale 
Steventon provides a strong argument and clear rationale for IM; the objective of preventing 
the outcome of interest is to achieve the PHM aims and RS alone, without consideration for 
impactibility, will not meet this objective (44). Interventions use limited resources therefore 
there is a need to increase the ‘value’ gained from resources spent. 
The problem of optimising health under constraints is one of seeking a higher ROI; for the 
cost incurred the greatest improvement to population health, patient experience and 
reduction to health inequalities is sought, i.e. the PHM aims. The objective of IM is to 
contribute to the ROI through population analysis to better target the allocation of resources 
to population need (approach B) or target the allocation of patients to interventions 
(approach A)  (16, 22, 24, 25).  
4.2.2.2 Theoretical proposals 
Theoretical approaches to IM are proposed predominately by Lewis (22, 24, 25). For the 
purpose of this dissertation, Table 2 categorises and summarises these; the first column 
shows proposals where the intervention is static, the second column where the intervention 
is dynamic, and proposals are then grouped by the nature of the criteria used in the model to 
understand impactibility. 
Proposals 1 to 3 suggest impactibility criteria based on disease, patient characteristics and 
risk strata for patient selection, discussed in Section 4.2.3.1. Proposal 5 requires further 
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research to understand the drivers of impactibility to allow interventions to be appropriately 
tailored to create an impact, discussed in Section 4.2.3.2.  
Table 2: Categories of proposed theoretical approaches to Impactibility Modelling 
Approach A Approach B 
Proposal 1: Disease based 
 
• Giving priority to diseases that are 
amenable to preventative care 
or  
• Focusing on impactable conditions  
 
Examples include 
➢ Analysis by disease measures  
➢ Analysing resources expected for a 
given condition 
Proposal 5: Patient characteristics 
based 
 
• Identifying forms of 
preventative care best 




➢ propensity to engage 
➢ patient activation measures 
➢ propensity to complete an 
intervention 
Proposal 2: Patient characteristic based 
 
• Excluding patients least likely to 
respond to preventative care 
 
Examples include 
➢ specific characteristics like language 
➢ stable characteristics like medication 
adherence 
Proposal 3: Risk strata based 
 
• Exclude high-risk patients 
 
Examples include 
➢ high-risk scores or rising risk scores  
Proposal 4: Service provision and 
utilisation 
 




➢ variability in utilisation  
➢ propensity to benefit scores 
Table is created based on proposals found in the literature (22, 24, 25, 43, 52, 56, 71-73) 
Proposal 4 based on service provision or utilisation will not be progressed here. These 
proposals limit the scope of resulting action to the health and social care system and do not 
truly assess an individual’s impactibility. This is because understanding why people are not 
provided with required interventions provides reflection on the quality in the delivery of 
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services, not a reflection on the impact created by the delivery of quality services. This 
distinction is not clearly established in the literature10.  
4.2.3 Impactibility criteria derivation 
Population analysis results in the derivation of criteria to base action upon. Impactibility 
criteria could concern the potential to mitigate the outcome of interest, or the patients’ 
willingness or ability to participate in an intervention (53, 74, 75). 
4.2.3.1 Criteria for patient selection 
Criteria for patient selection can be derived from clinical judgement, rules, or be data-driven 
(57, 74). Selection criteria can be inclusive or exclusive (7, 23, 25, 53). For example, an 
individual can be included for an intervention if at high-risk but excluded due to a lack of 
impactibility.  
4.2.3.1.1 Clinical Judgement 
Without PM, patient selection would be derived from clinical judgement as risk and impact 
assessments are part of daily practice (50, 53). Criteria are based on medical training, 
research and more subjectively, on previous patients’ experience, and ‘gut feelings’ (50, 53, 
71, 74-76).  
PM can be helpful for ‘case-finding’ under approach A, when faced with complex multi-
morbidity patients and increasing amounts of data to weigh systematically in clinical 
decision-making (10, 28). Currently, where patient selection is supported by RS it is 
supplemented for impactibility criteria outside of the model by applying clinical judgement to 
a shortlist of at-risk patients (16, 50, 53). 
4.2.3.1.2 Rules 
Criteria could be based on rules that formalise clinical judgement criteria (46). Cohen et al. 
provides an example of impactibility criteria derivation using disease and patient 
characteristics to explain impactibility, as suggested under proposal 1 and 2 (73). In this 
example of IM, clinicians short-listed a RS at-risk patient list and the rationale was then 
formalised into mainly exclusion criteria based on clinical assessment of ‘ability to benefit’ 
(73). A common clinical judgement impactibility exclusion rule removes shorter survival 
durations not expected to realise the benefit of the intervention (71, 73, 77).  
 
 
10 Further elaboration is provided in Appendix 3. 
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4.2.3.1.3 Data-driven 
Experience exhibited in routine health data can be leveraged to provide useful insight into 
risk (51). A threshold level of risk for patient selection can be created that strikes a balance 
between highlighting a sufficient number of people at-risk to have an impact on the PHM 
aims but not so many that action cannot be effectively implemented (22, 24, 73). This risk 
threshold could be leveraged as impactibility criterion (22, 24, 25, 73, 78); removing people 
at such high-risk that the benefit of the intervention is not expected to be realised. A worked 
example of proposal 3 is not available in the literature. 
Alternatively, impactibility criteria can be created based directly on the experience seen in 
the data. There are two data-driven IM examples in the literature under proposal 1, based on 
disease. Stokes et al. analyses, by measures of disease, the impact of case management on 
cost and care utilisations data (52). Buja et al. analyses sets of multi-morbidities expected to 
have similar utilisation as an explanatory variable for variations in hospital admissions (56).  
Patient can be included or excluded based on impactibility criteria. However, understanding 
the driver of risk and impact is the basis for resource tailoring. 
4.2.3.2 Criteria for resource tailoring 
IM for resource tailoring seeks to identify interventions best suited to patient characteristics 
(25), under proposal 5. This requires an understanding of the drivers of, not just an 
assessment of, risk and impactibility (79). Further secondary or primary research may be 
required to derive impactibility criteria (44, 49, 51, 72).  
Dubard and Jackson’s conducted secondary research on routine health data to identify the 
drivers of impactibility for patients with case management as an intervention (72). 
Demographic, clinical and utilisation variables were tested as potential drivers of 
impactibility, defined as potential cost savings. Medical adherence was found to be 
explanatory and provided insight on how interventions could be adapted to better achieve 
the PHM aims. 
There are limitations however on basing actions on insights from routine administrative data 
(80, 81). Data items, not collected for this purpose, may act as proxies for the underlying 
drivers of risk or impactibility (44). In addition, the drivers may not be present in the data (8, 
79) including social factors like relationships, language barriers, isolation, living 
arrangements and substance use (25, 82). Actions based on uninformative impactibility 
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criteria may be wasteful. Therefore, primary research may be required (44, 79, 82-84)11. 
Resource tailoring often requires further analysis of the drivers of risk and impactibility to 
create appropriate action such as altering patient behaviour or engagement, or altering the 
intervention to reflect patient preferences (13, 25, 44, 75, 79, 84-89). One of the PHM aims is 
patient experience, including quality and satisfaction (14) and a quality of care domain is 
patient-centredness (12). However, this area is under-represented in the literature. 
4.2.3.3 Criteria in combination 
Clinical judgement is susceptible to a range of cognitive biases (24, 53, 73, 74) and is less 
accurate in determining current risk (24, 33) than PM. However, it is more effective at 
predicting future deterioration of currently low-risk patients (90). Data-driven methods can be 
susceptible to regression to the mean where, even without the intervention, current high-risk 
patients are not future high-risk patients (8, 24, 57, 70). This implies less benefit is derived 
from the proactive provision of an intervention to a current high-risk patient than a rising risk 
patient. A study showed that patients independently selected by both clinical judgement and 
data-driven criteria had higher risk and impactibility. This, and other studies, suggests a 
combination of criteria derivation methods may be beneficial when designing IM (53, 74, 91). 
A model is a simplification of reality and as such PM is designed to aid, not replace clinical 
judgements (50). A predicted list of patients must be inspected in light of the complexities 
that are not present in the data (8, 74, 78). When implementing PM, it is more acceptable to 
allow clinical judgement to interact with PM in decision-making (27, 52, 53). The usefulness 
of PM output for practitioners is important (53) and building in common clinical judgment 
criteria improves acceptability such as survival duration (8, 53). Engagement with local 
healthcare teams and services users when deriving criteria establishes a better 
understanding and acceptance of the IM objectives (27), leading to more successful 
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The PHM system discussed so far is summarised in Figure 11. 
Figure 11: PHM summary – population analysis 
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4.3 The intervention 
Based on the results of the population analysis, action is taken in the form of an intervention. 
An intervention is considered here as any measure undertaken to prevent the adverse health 
outcome of interest. PHM can include interventions across both the health and social care 
system and the wider health system (10, 13). 
4.3.1 Possible interventions: stages of prevention 
Intervention can be provided at different stages of disease progression to prevent an 
adverse health outcome. The range of downstream to upstream interventions can be 
described as four prevention stages (92, 93), shown in Figure 1212.  
Figure 12: Intervention stages at each level of prevention 
 
Based on Disease prevention: a critical toolkit (93)(p.11) 
The restricted focus of the PM literature on outcomes of interest in the health and social care 
system (24, 44, 57, 65, 66), such as hospital admissions, appears to have restricted the 
intervention to tertiary prevention. This includes the improved management of patients with 
established disease (16, 26, 52, 94, 95). In the UK, this include case management, self-
management programmes, and altering the location of care delivery (4, 8, 24, 33, 34, 96). 
The literature highlights the need to consider primary prevention when discussing, at an 
individual level, the contributors to risk and impactibility such as housing, transportation, and 
behavioural aspects including medication exercise, diet, and substance use (8, 25, 75, 76, 
79, 97, 98). However, Stokes et al. stresses the importance of primordial prevention by 
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recognising that social factors ,that drive risk and impactibility, are “multifaceted, deeply 
ingrained and linked to the wider social context, and therefore highly resistant to change” at 
an individual level (8)(p.249).  
4.3.2 Delivering a stratified and targeted approach 
Rose describes a population and targeted approach to prevention (99). A middle ground of a 
stratified approach is put forward by Lewis which sees population analysis leveraged to 
target preventative action; people are assigned to different interventions dependent on risk 
and impactibility (22, 28, 57). In Somerset and Salford, UK all population ‘risk’ levels are 
targeted in some respect (8); prevention is targeted at high-risk patients but also provision 
made for prevention to low-risk patients (67). 
Therefore, impactibility criteria could be used a rationale for intervention and prevention 
stage choice. Those impactable by an intervention can be targeted in patient selection (22) 
and those less impactable could be the target of earlier prevention (8). Importantly, a lack of 
impactibility is not a reason not to take action and, at the least, should be the reason for 
reviewing the effectiveness of and seeking improvements to interventions to better achieve 
the PHM aims (22).  
The PHM system detailed so far is summarised in Figure 13. 
Figure 13: PHM summary – intervention 
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4.4 The evaluation 
When the intention is to iteratively develop a solution within an LHS, the merit of PM may not 
be judged on its initial implementation. This may also limit the ability to simultaneously 
evaluate models in different locations (100); the model will be in different stages of 
development and specific to the context.  
However, a plan for the evaluation is required. The literature comments on a lack of clarity in 
defining evaluation terms in advance and a lack of clarity in assessing PHM systems overall, 
against the PHM aims, and each component part for accuracy and effectiveness (27, 35). 
4.4.1 Overall PHM system 
The uncertainty regarding the success of PHM systems is apparent in the literature (8, 24, 
44, 67, 101-104). This appears to stem from a lack of clarity and preparedness for the 
evaluation. When assessing the PHM system overall, the evaluation requires consideration 
for the terms and method. 
The terms of the evaluation must be established. The literature reviewed primarily concerned 
reducing hospital admissions or costs for high-risk and high-cost patients (8, 24, 25, 35, 52, 
56, 67, 72, 105, 106). Case management, as an intervention, can increase patient 
satisfaction (95) and health status but at the expense of increasing utilisation and costs (52). 
However, if unserved needs are met this may not be a failure overall (52, 107). PHM should 
enable savings that recoup its cost (22, 24, 57). However, the overall objective is to optimise 
population health under constraints so measuring costs alone is not sufficient to warrant 
success. How the design of IM proposals influence health inequalities and patient 
experience is commonly not commented on which makes the terms of evaluation unclear 
(35). 
The literature is not explicit on the relative importance of each of the PHM aim however, 
having a clear understanding on the priority of the aims in the local context is suggested to 
be a contributor to successful PM implementation (8, 27, 44, 75). The first step in designing 
a PHM system is to understand the nature of the problem faced (44). This requires analysts 
and modellers to work in close collaboration with local practitioners, patients and the public 
representatives (44). A clear understanding of the problem faced in the local context may 
allow for clear evaluation metrics to be agreed in advance and defined to mirror local priority 
of the aims. 
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An evaluation method must be chosen to ensure a valid comparator group (24, 57). 
Evaluations must account for ‘regression to the mean’ (67) and supply induced demand13 
(33, 57, 67). Lewis states that working collaboratively across NHS organisations to pool data 
for evaluation may be beneficial (24). However, what is gained through increased relevance 
to the local context when designing IM may be lost in generalisability for a pooled evaluation. 
A PHM system may need to be in place for some time to see an effect to the overall 
objective, so defining key performance indicators (‘KPIs’) of success in the short, medium 
and long term that account for variation by chance over those time periods, would be 
beneficial (28, 67).  
4.4.2 Component parts 
The PHM system has two parts for success: choosing the right people (population analysis) 
and providing a quality programme (the intervention) (71). 
PM tools will never be fully accurate, as models are only representations of reality. There 
may be potential negative consequences of false positives (providing an intervention when it 
is not needed) and false negatives (not providing an intervention when it is needed) (24, 25). 
Population analysis can be evaluated on model fit to historic data and predictive accuracy 
(24, 25, 57, 59, 63). The well-developed RS literature can be leveraged here for IM, although 
the suitability of the measure will vary depending on model (57, 59)14. 
An evaluation of intervention effectiveness can be multifaceted. In an LHS, comparative 
effectiveness research can assess the impact created by an intervention in a population (28, 
80). IM could be used to compare population effectiveness to the proposed efficacy (24, 71). 
This may assist decision-making on when to cease an ineffective intervention to better 




13 Supply induced demand refers to a situation where if resources are ‘freed-up’ these will 
subsequently be used. Also known as Roemer’s law; ‘a hospital bed built is a hospital bed 
filled’. 
 
14 Further commentary is provided in Appendix 7 on these measures. 
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The PHM system detailed so far is summarised in Figure 14. 
Figure 14: PHM summary – evaluation 
 
4.5 A Learning Health System control cycle 
In an LHS, the continued development of IM makes it part of an agile solution (22, 24, 41). A 
plan should be agreed on how frequently models are run, recalibrated and rebuilt as required 
in the cycle (57). 
The Actuarial Control Cycle, shown in Figure 15, has two additional elements, environment 
and professionalism, which promote the creation of an agile solution. These ensure the cycle 
is appropriate and responsive to the context and upholds professional standards including a 
duty to act in the public interest (108). 
Figure 15: Actuarial control cycle 
 
Based on an Actuarial profession publication (30)  
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The impact of a model’s context on its design and the impact of the model on the context in 
which it is used must be consider as organisational aspects can undo efforts of any system 
(16). Uptake of IM by stakeholders is improved when clarity is provided on how IM 
contributes to population health (27, 41, 44). A model must be accepted and adopted within 
its context to be successful (16, 27). This requires training, adequate support (27) and 
communication and mutual learning between stakeholders (16, 41, 57).  
Professionalism is required to ensure that the PHM systems works toward achieving the 
PHM aims in an ethical way, in line with the public interest (108). An adapted Wilson Jungner 
criteria 15(22, 109), shown in Table 3, or an LHS ethics framework may be relevant (110) for 
an IM ethical review. There are two areas of the literature, incentives and inequality 
concerns, that need further consideration. 
Table 3: Adapted Wilson & Jungner criteria for Population Health Management 
1. The event being predicted should be an important health problem. 
2. There should be an accepted intervention that can mitigate the risk of the event 
that can be offered to high-risk patients. 
3. Resources and systems should be available for timely risk stratification and 
provision of preventative interventions. 
4. There should be sufficient time for intervention between risk stratification and 
occurrence of the event. 
5. Sufficiently accurate predictive models for the event should be available, 
including risk stratification and impactibility models. 
6. The predictive modelling tools should be acceptable to the population at large. 
7. There should be an accepted policy about who should be offered the 
preventive intervention. 
8. The natural history of the adverse event should be adequately understood by 
the organisation offering the preventative intervention. 
9. The cost of stratification should be ‘economically balanced’, i.e. it should not be 
excessive relative to the cost of the program as a whole. 
10. Predictive modelling stratification should be a continuous process, not just a 
‘once and for all’ occurrence. 
Adapted to table format, text sourced from Lewis (22, 24) 
 
 
15 Wilson & Jungner criteria are an established means of creating a balance between the 
harms and benefits of screening in secondary prevention  
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4.5.1 Incentivisation of the control cycle 
The ongoing management of the control cycle can be tied to performance objectives and 
financial remuneration (22, 25, 69). Reducing hospital admissions has been formally linked 
to financial incentives in many countries including England (44, 69).  
Where KPIs are set in relation to the PM outcome of interest instead of directly to the PHM 
aims, the incentive to manage the control cycle may result in unintended consequences or 
mal-incentives (23, 107, 111). For example, reducing hospital admissions may reduce costs 
at the expense of health status or patient satisfaction, therefore working against the PHM 
aims (23). The literature shows many cases of PM designed to align with reducing hospital 
admissions, the basis for financial remuneration, in lieu of the PHM aims (44, 65, 67). 
4.5.2 Inequality concerns 
Prioritisation vs rationing in the allocation of resources is an integral difference between RS 
and IM and appears to be the driver of equity of access and health inequality concerns (8, 
22-25, 28, 74, 75). It may be reasonable for a group at high-risk of an adverse health event 
to be prioritised over others, given limited resource (74), similar to triage (46, 76). However, 
IM suggests, under approach A, that there are some people for whom it is not worth 
providing an intervention to, even with a higher risk of the outcome (22, 23, 25). This implies 
an unjust access to healthcare (24, 28, 74). In the UK, equity in access is key to the NHS 
values (4, 112) and so IM used in this way may not be acceptable to the public (criteria 6 of 
Table 3). 
A potential pitfall of IM comes from linking the impact (health outcomes) to the provision of 
an intervention (the access). Where those not selected by IM may be more likely to come 
from marginalised or disadvantaged populations characterised by health inequalities (74, 
75). A spiral of unjust distribution of health outcomes could result, deepening health 
inequalities (22-24) and working against one of the PHM aims. 
An ethnographic study in the US has shown an entangling, in terms of ROI, to the 
neoliberalist private approach to health care and IM (76). By striving to reduce costs, high-
risk high-cost patients are targeted with interventions to reduce utilisation. This implies 
improved health and reduced costs, two of the PHM aims and as a by-product it reduces 
health inequalities by targeting those with poor health outcomes with a greater potential ROI. 
Therefore, it cannot be assumed that IM is in direct contradiction to a just distribution of 
resources nor to reducing health inequalities.  
It could be suggested that withholding access to an intervention is not unjust if it is not 
appropriate for the individual patient (28, 113). However, failure to invest in the creation of, or 
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allocation of funds to, appropriate interventions could be unjust. IM under approach A may 
see access reduced for non-impactable people however, approach B may see resources 
tailored or allocated to improve impactibility. Therefore, the differentiation between approach 
A and B in the design of the PHM system is relevant to the acceptability of IM (24). 
The potential for IM to deepening health inequality requires PHM to be designed, and the 
control cycle managed, to actively reduce or monitor the impact to inequalities (22, 25, 74). 
Using socio-economic indicators in PM and/or embedding clinical judgement may overcome 
inequality concerns (74). It is recommended in the literature that concerns be actively 
addressed to maximise the potential of IM (22, 23, 28, 67). 
4.6 Literature review conclusion 
In summary, the literature related to IM primarily concerns the rationale and theoretical 
approaches with few worked examples. There is a cautious yet optimistic view of its potential 
to better achieve the PHM aims and navigate health system sustainability pressures. 
IM is part of population analysis, but it interacts with the intervention and the achievement of 
PHM aims, assessed in the evaluation. The literature does not adequately reflect this, 
implying that the need for IM to be developed, implemented and assessed as an agile 
solution may not be fully appreciated. 
4.6.1 Summary of IM examples 
The few IM model found develop different proposal using different impactibility criteria. The 
predictive accuracy is not comparable and the PHM systems are too young to assess the 
contribution to the PHM aims. There are fewer developments under approach B and none 
yet for proposal 3. The model used varies which may indicate that IM will develop as a 
selection of models in lieu of a single ‘best’ model type. The models have developed in 
different locations showing the commonality of the problem, to optimise health under 
constraints, but the variation in explanatory variables and outcomes of interests show its 
dynamic nature. In most cases the link to the PHM aims is weakly established or indirect, as 
shown in Table 4.  
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Table 4: Summary of Impactibility Modelling examples 
Authors PHM approach 
/  
IM proposal 
Outcome of interest 
/ 
Link to PHM aims 
Explanatory variables 
/ 
Link to PHM aims 
Criteria derivation Location 
/  
Model type 
Cohen et al. 
2015 
(73) 
Approach A  
 
Proposal 1 & 2 
Improve cost-
effectiveness of case 
management 
 
Implied PHM aims of 
reducing costs and 
improving health 
 
The link is indirect 
Patient characteristics and 
medical complexities such as 
active cancer, schizophrenia, 
resident in a nursing home, care 
arrangement or age.  
Not explicit on implications to 
PHM aims 
Impactibility criteria 
are rules for exclusion 






IM is built as a  
refinement to RS 
model using 
routine health data 
 






Hospital admissions for 
heart failure patients 
 
Implied PHM aims of  
reduce cost and improve 
health 
 
The link is indirect 
Algorithm based on clinical 
judgement for morbidity 
groupings for expected 
utilisation  
 
Not explicit on implications to 
PHM aims 
Impactibility criteria 
are data-driven criteria 
from routine health 
data 
 
Using a variable 
defined by clinical 
judgement to form 
homogeneous sub-






IM built as a 
refinement to RS 
model using 
routine health data 
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Authors PHM approach 
/  
IM proposal 
Outcome of interest 
/ 
Link to PHM aims 
Explanatory variables 
/ 
Link to PHM aims 











intervention as measured 
by secondary care 
utilisation and cost 
measures 
 
Implied PHM aims of 
reducing cost and 
improving health 
 
Direct link made to cost 
Disease measures including 
counts, clusters, complexity, 




Not explicit on implications to 
PHM aims 
Impactibility criteria 
are data-driven based 





IM built using 
difference- in -










effectiveness of case 
management defined as 
potential cost saving 
(expected vs actual cost) 
 
Direct link to PHM aim of 
reducing cost. 
Demographic, clinical and 
utilisation characteristics 
 
Not explicit on implications to 
PHM aims 
Impactibility criteria 
are data-driven based 





IM built using 
linear regression 
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4.6.2 Recommendations for development and application in 
practice 
Common themes in the recommendations have been distilled into an ethos of IM including 
the need for: awareness, clarity, collaboration, preparedness and work across a wider health 
system. Where these recommendations are apparent from the literature these are 
summarised, in Table 5, without further elaboration.  
The objective of PHM is to optimise health by working across the wider health system, 
inclusive but not restricted to the health and social care system. In the literature, there is 
potential for IM to develop with a restricted scope; proposal 4 limits the potential of 
population analysis to the health and social care system, as does a focus on tertiary 
prevention.  
Structural changes, considered necessary for the sustainability of the UK health system, 
require action and collaboration across the wider health system (4, 5). Engaging wider health 
system stakeholders including local communities, authorities, and employers and adopting 
earlier prevention to tackle modifiable risk factors are key to the addressing sustainability 
pressures (4). In PHM, resources are allocated in the most effective to optimise health(10) 
and a better understanding of the drivers of risk and impactibility, may more effectively direct 
resources to public health. 
If the means of achieving cost savings is to be prevention of 
medical and social needs (and a resulting reduction of demand on 
services), then broader, population wide, approaches might prove 
better use of resources rather than the current focus on selecting 
specifics patients for intensive health care services. (8)(p.249) 
To achieve PHM aims, analysis and action should not be restricted in view (8, 13, 23, 55, 
75). A specific recommendation is made here to ensure that work across the wider health 
system is paramount at this early stage of IM development.  
Table 5: Impactibility Modelling recommendations – An ethos of IM 
A Awareness 
A1. The role IM plays within a PHM system, depends on the approach adopted (A or 
B) which alters the design and objectives of IM. Those adopting IM should be 
cautiously aware of the ethical implications and the acceptability of IM under each 
approach. 
A2. Awareness of the timeliness, quality and adequacy of routine administrative 
health data for deriving impactibility criteria is required. Further analysis may be 
required to understand the drivers of impactibility. 
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A3. Impactibility criteria can be based on clinical judgement, rules, and data-driven 
methods but developers should be aware that a combination of these criteria may 
be more effective. In addition, a model that includes common clinical judgement 
criteria and a model that interacts with clinical judgement may be more 
acceptable. 
A4. Developers should be cautiously aware of the implications of existing financial 
incentives and the role they play in the design of IM. 
A5. Those adopting and developing IM should be cautiously aware and actively 
consider the ethical implication of each element of the model design.  
A6. Awareness should be brought to the PHM aim of patient experience and how it 
will be represented and measured. 
B Clarity 
B1 Developers should be clear on the objectives of the PHM system. 
Clarity is required on why and how managing the outcome of interest is expected 
to achieve the PHM aims. In addition, clarity is required on how the choice of 
explanatory variables has implications on the achievement of each PHM aims.  
 
Best practice may be to create a direct link to the PHM aims where possible or to 
be explicit in the assumption of an indirect link to the PHM aims. 
B2 Being clear on the relative importance of each PHM aim in the local context is a 
crucial stage in IM development. 
This is expected to improve inter-professional communications regarding the 
objectives of IM and provide clear evaluation terms. 
C Collaboration 
C1 The nature of the problem faced must be understood first when developing IM. 
This requires analysts and modellers to work in close collaboration with local 
practitioners, patients and the public representatives. This is also beneficial when 
defining evaluation terms in advance. 
C2 Engagement with local healthcare teams and services users when deriving 
impactibility criteria is considered beneficial for successful implementation. 
C3 Successfully embedding IM into an LHS requires training, support and proactive 
inter-professional communication. However, it also requires mutual-learning and 
establishing a common objective across stakeholders; to optimise health under 
constraints. 
D Preparedness 
D1 The evaluation should be set out in advance. This will require a decision on: 
method, data, and terms of success including the relative weight of the PHM aims 
and short, medium and long-term KPIs.  
D2 Intended and unintended consequences should be documented for regular 
evaluation. The risk of unintended consequences and mal-incentives should be 
explicitly considered during the design and objective setting of IM and PHM 
evaluation. 
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D3 IM developers will need to agree an ethical framework in advance for model 
design and implementation. Although models may be designed and implemented 
at a local level, it may be more suitable to agree an ethics framework at a more 
strategic level. 
D4 IM should be tested for fit to the historic data and predictive accuracy. IM should 
be evaluated against its ability to contribute to each of the PHM aims. It could be 
used in comparative effective analysis of interventions. 
E Work across the wider health system 
E1 When developing IM, it is important to consider its wider context in the PHM 
system and LHS.  IM proposals should not limit the potential of PHM solutions to 
action within the health and social care system alone. Wider health system 
changes may be required to accommodate the dynamic problem of optimising 
health under constraints. 
E2 Interventions from upstream to downstream prevention should be assessed for 
impactibility. A lack of impactibility is not a reason not to act. Impactibility criteria 
can be leveraged to stratify and target intervention at earlier prevention stages. 
Alternatively, it should be used as a reason to improve interventions 
effectiveness. 
E3 Designing IM in a PHM system for the better achievement of the PHM aims may 
not the same as designing IM to meet current financial incentives. PHM systems 
and IM models should be designed to meet the PHM aims (over current financial 
remuneration incentives). 
4.6.3 Search strengths and limitations  
Email correspondence with Lewis on 27 August 2019, gave confidence in the relevance and 
breadth of the literature captured. Seed authors are likely to cite their own or colleagues 
works which may have reduced the breadth of literature. However, the lack of new literature 
from the term search was reassuring.  
This literature search is less reproducible16 and the varied nature of the literature did not lend 
itself toward meaningful meta- or quality analysis. However, this was not required to achieve 
the objective of this review.  
The literature found is believed to be an adequate reflection of IM, but it is only a small 
proportion of PHM literature. The narrower search criteria may mean some areas relevant to 
the development of IM are not included.  
 
 
16 For transparency and completeness, Appendix 4 lists literature by relevance including 
those not considered relevant 
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Chapter 5 Proof of concept 
5.1 Case study 
Type 2 Diabetes Mellitus (‘T2DM’) is used as a case study for the proof of concept. Chronic 
diseases are long term conditions that cannot currently be cured but are controlled with a 
range of interventions and therefore contribute to demand-side pressures on a health system 
(26). T2DM “is a chronic metabolic condition characterised by insulin resistance ..and 
insufficient pancreatic insulin production, resulting in high blood glucose levels” (114) (p.6). 
The incidence and prevalence of the disease has been increasing in the UK (115), as shown 
in Figure 16, and the disease burden anticipated to increase in the future (116).  
Figure 16: Prevalence and incidence of T2DM in England, Scotland and UK 1990-2017 
 
Images sourced from IHME (115) 
In the UK, the NHS Health Check provides secondary prevention screening for T2DM every 
5 years from age 40 to 74 (117). At the same time, primary prevention is provided with 
advice on modifiable risk factor management to reduce the risk of T2DM (117). 
5.2 Aims and objectives of proof of concept 
To extend the development of IM, this proof of concept will expand on the clarity and 
awareness recommendations from Chapter 4 in the following ways: 
• show how a model design can be directly associated with the PHM aims or explicit in 
the assumption of an indirect relationship; 
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• bring awareness to the implication for health inequalities of IM by testing socio-
economic indicator as an impactibility criterion. At the same time, this shows how 
inequalities could be monitored on an ongoing basis; and 
• show impactibility in terms of a modifiable risk factor thereby highlighting the 
importance of earlier stages of prevention to manage the outcome of interest. 
The objective of this proof of concept is to explore the usefulness of MSM for the purpose of 
IM by: 
• assessing if the model choice is suitable for routine health data; 
• assessing if the model output can be used to interpret impactibility; 
• showing how it could be used to derive impactibility criteria; 
• providing output that can be used to evaluate IM accuracy; and 
• providing output that can be used to evaluate intervention effectiveness. 
To achieve these aims the following steps were undertaken: 
1. Outline the theoretical suitability of MSM for application to routine health data, 
chronic disease analysis and various IM purposes; 
2. Source routine health data which contains anonymised medical and demographic 
data including health outcomes; 
3. Design and describe the cohort extracted suitable for a proof of concept analysis; 
4. Consider potential sources of bias and confounders; 
5. Define the IM outcome of interest and explanatory variables in direct relation to PHM 
aims and/or be explicit in the assumed indirect link to the PHM aims; 
6. Describe the data used in the model including patient observations; 
7. Describe the transition intensities, transition probability, mean sojourn times and 
total length of times in terms of impactibility; 
8. Test if socio-economic indicator differentiates transition intensities; and 
9. Test the model for fit to historic data and predictive accuracy. 
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Chapter 6 Methods 
This chapter details the rationale for multi-state modelling (‘MSM’) as a method for IM and 
provides a description of the method as applied to T2DM. 
6.1 Rationale for approach 
MSM is suitable for PM as it “provides a natural and powerful framework” for describing and 
analysing life history processes and for that reason it is used in medicine, public health, 
economics and social sciences (118)(p.xiii). The outputs contain insights to “the probability of 
moving from one state to another, and the duration of spells spent in specific 
states”(118)(p.2) which are useful for interpreting impactibility when related to a cost or 
health state. 
MSM “can be used to address a wide range of issues related to chronic diseases”(118)(p.6) 
so is applicable to the case study and a source of sustainability pressure. The model can be 
used for many objectives, as shown in Table 6, which not only align with the data-driven 
derivation of impactibility criteria but also with resource allocation and intervention 
evaluation. 
Table 6: Multi-state modelling objectives 
1 increasing the understanding of individuals’ processes and of variation across 
individuals, groups or populations; 
2 identifying and characterizing relationships between processes and covariates, 
or between two or more processes; 
3 identifying risk factors associated with adverse outcomes; 
4 assessing the effectiveness of individual or population level interventions; and 
5 developing predictive models that can be used for activities such as resource 
allocation, policy formulation and patient management 
Sourced from Cook & Lawless (118)(p.12) 
MSM uses longitudinal data which covers an individual’s life over a period of time including 
medical events and patient characteristics (118). It can accommodate routine health data of 
intermittent observation and uninformative truncation or censoring 17.  
 
 
17 For background information on the method, a working description of MSM theory is 
provided in Appendix 8. 
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6.2 Description of the methods 
An individual’s life history is considered as “represented by time spent in states and 
movement between states” (119) (p.256). An individual can occupy one of the possible 
“‘states’ at any given time and moves between states at random times governed by the 
probabilistic model” (119) (p.xv). To apply MSM, a state space and transition intensity matrix 
must be defined, and life history data sourced to populate the matrix. A description of how 
MSM is applied to T2DM for the objective of IM is provided here18. 
6.2.1 State space 
In this proof of concept, the management of the outcome of interest is related directly to the 
management of the disease and therefore the PHM aim of improving health status. Two 
models are defined based on measurements in the T2DM care guidelines (114, 120). 
Haemoglobin A1c (‘HbA1C’) is a clinical measure used for diagnosis and ongoing disease 
management; it is a measurement of blood glucose levels in the last 3 months (114, 121). 
Body Mass Index (‘BMI’) is a modifiable risk factor for T2DM before diagnosis and a target of 
lifestyle interventions after (114, 122). To overcome issues of short-term variation and 
measurement error when using raw biomarker values, states are defined in terms of ranges 
(118). 
A deceased state is added to both models, as an absorbing state, to account for mortality 
risk during the period.  
6.2.1.1 BMI model 
For BMI, the well-established ranges shown in Table 7, are adopted for the model states 
(122). 
Table 7: BMI ranges by nutritional status 
BMI Nutritional Status 
Below 18.5 Underweight 
18.5 – 24.9 Normal weight 
25.0 – 29.9 Pre-obesity 
30.0 – 34.9 Obesity Class I 
35.0 – 39.9 Obesity Class II 
40 and above Obesity Class III 
Categorisation as provided by World Health Organisation(122) 
 
 
18 For background information on the method, a working description of MSM theory is 
provided in Appendix 8. 
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The underweight category is grouped with normal weight due to a lack of data which creates 
the state space represented in Figure 17. 
Figure 17: BMI model state space 
 
6.2.1.2 HbA1c model 
Once diagnosed, ranges of HbA1c are used to categorise the management of the chronic 
condition, as shown in Table 8. 
Table 8: HbA1c ranges by diabetes control 
HbA1c % mmol/mol Diabetes control 
Below 5.9 31 - 49 Excellent 
5.9 – 6.6 50 - 55 Good 
6.7 – 7.2 56 – 60 Poor 
7.3 – 8.6 61 – 70 Less than poor 
 8.7 and above 71 + Very poor 
Categorisation from Southend NHS (123) 
These ranges have been adopted as states for the model, as represented in Figure 18. 
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6.2.2 Transition intensity matrix 
Transition intensities are the forces to which an individual is subject; keeping the individual in 
the current state or transitioning to another state. Data is analysed to populate the transition 
intensity matrix, Q, as shown in Equation 1. Transitions that are not possible in the process 
are set to zero. The instantaneous transition rate to remain in the same state is the negative 
of the sum of transition rates to leave the state i.e. 𝜇𝓍
11 =  −(𝜇𝓍
12 + 𝜇𝓍
16). The structure of the 
matrices is the same for both models as there is the same number of states and allowable 
movements between states. 
Equation 1: Transition intensity matrix 



















































6.2.2.1 Explanatory Variable 
Testing for an explanatory variable is the first step in deriving impactibility criteria. In a MSM, 
an explanatory variable can be added to the model to test if transition rates vary significantly 
by that factor. 
The PHM aim of reducing health inequalities is built directly into this proof of concept by 
testing the socio-economic indicator, Scottish IMD19, as an explanatory variable for 
impactibility. IMD is known to be correlated with health inequalities (124, 125). Two IMD 
groups are created; most deprived including IMD deciles 1 to 5 and least deprived including 
deciles 6 to 10. 
If transition rates toward unhealthier ranges of BMI and HbA1c (progression through states) 
are higher or if transition rates toward healthier ranges of BMI and HbA1c (regression 
through states) are lower – then a patient would have lower impactibility. By testing if 
transition rates vary by IMD, an awareness is brought to the implications of IM for health 
inequalities under approach A or B. 
 
 
19 The Scottish Index of Multiple Deprivation (‘SIMD’) is used in this dataset and is referred to 
hereafter as IMD. 
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6.2.3 Data 
Individual life history data is required to populate the transition intensity matrix. There are a 
number of BMI or HbA1c observations recorded in a patients’ data and these are considered 
as events in MSM. 
6.2.3.1 Source 
Retrospective cohort data access was agreed for research purposes with the University of 
Edinburgh20. The Scottish Care Information (‘SCI’) diabetes epidemiology database21 is a 
population disease register for diabetes in Scotland sourced from linked routine primary and 
secondary care health data with good coverage (126). The 2016 dataset is the most recent 
available which contains anonymised and cleaned medical event and demographic data for 
patients with T2DM. 
6.2.3.2 Cohort 
To account for confounders a fully comprehensive model would need to be more complex 
than is within the project scope. In the spirit of a proof of concept and for model parsimony, 
simplifying criteria are applied to create a more homogeneous test cohort. A summary of 
these criteria provided in Table 9. 
Table 9: Defining cohort criteria 
Criteria Restriction 
Time period Events occurring between 01/01/2011 and 15/07/2016 
Diabetes type T2DM excluding gestational and secondary diabetes 
Gender Both men and women 
Age Aged [40, 49] at diagnosis 
Durations First 5 years following diagnosis  
Intervention All under ‘current practice’ 
The time period is defined to ensure the cohort represents the most recent period in the 
dataset for which there are no material changes to guideline interventions (114, 120). 
Analysis is restricted to T2DM in adults excluding secondary and gestational diabetes to 
mirror care guideline (114). Ages 40 to 49 at diagnosis, inclusive, represent the youngest 
range of the target T2DM primary and secondary prevention ages (117) where the 
prevalence of multi-morbidities is anticipated to be lower than older target ages. Age is likely 
to be an explanatory variable (127-129) but the transition rates are assumed not to vary 
materially in the 10-year range for the proof of concept. Duration since diagnosis may be an 
 
 
20 A Level 1 Ethics form is provided in Appendix 1, no further review was required. 
21 Referred to hereafter as the SCI database 
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explanatory variable in the control of HbA1c (130) or BMI. For simplicity, the first 5-years 
after diagnosis are chosen for the cohort and it is assumed there is not a material change in 
transition rates over this period. 
Population level data may indicate impactibility for a given intervention however, to allow for 
a simplified analysis, this proof of concept assesses the range of guideline interventions 
used in the first 5-years of diagnosis under ‘current practice’. Guidelines include lifestyle 
changes, patient education and self-management alongside medicinal therapy (114, 120). 
There will be variation to suit the individual (114, 120) but it is assumed that care is 
adequately and appropriately provided as T2DM is an ACSC with an established Audit and 
Feedback practice, linked to Quality and Outcome Framework (‘QOF’) for practitioner 
remuneration (131). 
6.2.3.3 Potential sources of bias 
The data is assumed to be representative of the Scottish T2DM population with limited scope 
for selection bias (126). The retrospective data is based on routine health data; patients are 
not self-selected for research.  
The cohort includes patients in allowable states between the study start and end dates. 
HbA1c is recorded for over 90% of the population and BMI for over 80% (132). There is 
considered to be no bias in the patients missing HbA1c or BMI, as these are measures for 
disease management (132, 133). In addition, only patients with more than one observation 
are included to allow for time between events to be analysed. Patients with only one event in 
a 5-year period are not assumed to be inherently different.  
The data covers all of Scotland so ‘loss to follow up’ bias is limited to emigration out of 
Scotland in a 5-year period. Right censoring where patients leave before an event occurs is 
allowed for in the state space by ensuring all modes of exit are accounted for. It is assumed 
there are no other material forms of exit than death. 
Only patients diagnosed after the study start date are included which removes left censoring 
and truncation issues where people are at-risk, or the event occurred, before the study start 
date, respectively. 
MSM can cope with non-informative left-truncation and right-censoring as the indicator 
function considers time under observation only. Based on the above, it is assumed both are 
non-informative within the dataset.  
In observational data “the collection of data can occur sporadically at times that vary from 
individual to individual” (118)(p.3). This is common to routine health administration data 
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where an observation is made if the individual presents to the medical system. MSM is 
suitable for analysis of this ‘panel data’ with intermittent observation (118). 
The provision of private health care for chronic disease is considered not to be material. 
Therefore, the risk of event data being recorded outside of the database is considered 
minimal as the SCI database links public primary and secondary care. Patients missing 
postcode removed only 0.2% of the cohort and is not considered to introduce bias. 
Some data may be recorded with greater accuracy in observation data than others. For 
states other than deceased, the dates are assumed to be non-exact (observational), but date 
of death is assumed to be exact in the model design. 
6.2.4 Computation, data manipulation and model testing 
The msm package in R is used for computation (134). This off-the-shelf model has a useful 
guide (134) and based in a free access programme making it appropriate for work in multi-
disciplinary teams and across institutions. A data frame of a counting process format is 
prepared with the variables: unique ID, state, time, IMD group22. 
The model should be capable of generating the observed data (119)(p.258) when well fitted 
therefore it is important to create two datasets to prevent overfitting; one to train the model 
and another to validate predictive accuracy (25). The full dataset is split into a training (75%) 
and validation (25%) dataset using uniform distribution random numbers. As the model was 
not fit on the validation data, it provides an indication of the predictive accuracy. 
The model build is specified by the state space and the transition matrix. Under each model 
transition rates were solved for and then IMD group tested as an explanatory variable. No 
model selection was required as this proof of concept only tests if the covariate provided 
explanatory power. Suitable MSM diagnostic checks of Observed vs Expected analysis are 
performed. 
6.2.5 Potential confounders 
Variation in the ability to control HbA1c or keep a healthy BMI following diagnosis may vary 
by gender, age, duration, and morbidity (135, 136). The affect by IMD may be confounded by 
the variation of these factors by IMD group in the data. Evidence of possible confounding 
was analysed for these four factors using visual graph comparison.  
 
 
22 An example data frame is provided in Appendix 9 
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It is not possible to check due to poor data coverage but there may be a bias in the 
distribution of ethnicity by IMD. It is assumed that there is no bias in medical adherence by 
IMD group under free healthcare and affordable prescriptions. There is likely to be smoking 
prevalence bias by IMD group however, smoking is not considered to impact BMI or Hba1C 
(137).  
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Chapter 7 Results 
This chapter provides a data summary and results for each model. 
7.1 Data summary 
7.1.1 Count of patients 
A total of 11,240 patients were included in the BMI model and 13,364 in the HbA1c model, 
as shown in Table 10 and Table 11. Approximately 60% of T2DM patients are in the most 
deprived IMD group. 
Table 10: BMI data summary - count of patients 
Dataset Full Training Validation 
Total patients 11,240 8,485 2,755 
Most deprived IMD[1,5] 7,118 5,384 1,734 
Least deprived IMD [6,10] 4,122 3,101 1,021 
Table 11:HbA1c data summary - count of patients 
Dataset Full Training Validation 
Total patients 13,364 9,902 3,444 
Most deprived IMD[1,5] 8,485 6,310 2,175 
Least deprived IMD [6,10] 4,879 3,610 1,269 
 
7.1.2 Count of observations 
The median number of observations per patient in the data is 4 for BMI and 6 for HbA1c in a 
5-year period. The number of observations is similarly distributed by IMD group, as shown in 
Table 12 and Table 1323. This implies that one group is not contributing more information to 
a model than the other. 
Table 12: BMI data summary - count of observations 
Dataset Full Training Validation 




All IMD All IMD 
Min 2 2 2 2 
Q1 3 3 3 3 
Median 4 4 4 4 
Q3 6 6 6 6 
Max 74 54 74 31 
Mean 4.86 4.77 4.81 4.77 
 
 
23 A graph of the distribution of observation is provided in Appendix 11. 
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Table 13: HbA1c data summary - count of observations 
Dataset Full Training Validation 




All IMD All IMD 
Min 2 2 2 2 
Q1 4 4 4 4 
Median 6 6 6 6 
Q3 8 9 8 8 
Max 33 40 40 33 
Mean 6.37 6.45 6.42 6.36 
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7.1.3 Observed transitions 
The transitions between states observed in the training datasets, shown in Table 14 and 
Table 15, are used to populate the model24. 
This can be read as there were 35 transitioned from a state of Pre-obesity to Deceased. 
There were 7,996 observation of Obesity 1 followed next by an observation of Obesity 1. 
Table 14: BMI observed transitions 












Under/Normal 2,000 187 2 0 0 25 
Pre-obesity 225 4,931 510 1 0 35 
Obesity 1 2 614 7,996 517 1 31 
Obesity 2 1 2 700 6,314 403 23 
Obesity 3 0 0 8 560 7,259 29 
Deceased 0 0 0 0 0 0 
When most of the observations lie on the diagonal of the matrix, i.e. not changing state, the 
process is said to be more stationary. The BMI process is more stationary than HbA1c, as 
seen in Table 15. 
Table 15: HbA1c observed transitions 
 State To      





Excellent 10,580 2,232 653 493 374 57 
Good 2,233 3,261 1,456 1,217 762 20 
Poor 715 1,308 1,433 1,389 831 12 
Less than poor 761 1,308 1,471 3,166 2,191 19 
Very poor 794 935 969 2,905 10,123 50 





24 Observed transitions by IMD group are shown in Appendix 11. 
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7.2 Potential confounder analysis 
There is no visible bias in the distribution of data by IMD group by gender (Figure 19), age at 
diagnosis (Figure 20) or duration since diagnosis (Figure 21). 
Figure 19: Gender distribution of patients by IMD 
 
Figure 20: Age at diagnosis distribution of patients by IMD 
 
 
Figure 21: Year of diagnosis distribution of patients by IMD 
 
There is no visible bias in the prevalence of morbidities by IMD in Figure 22 and Figure 23. A 
modified Charlson Index (138, 139) shows the severity of existing morbidities in the 10-years 
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prior to diagnosis25. There is a bias toward morbidities especially at higher severities in the 
most deprived group however, this is limited for more sever morbidities to around 1%.  
Figure 22: Morbidity distribution of patients by IMD – BMI dataset 
 





25 Code was kindly sourced from Kelly Fleetwood at the University of Edinburgh. 
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7.3 Rates 
From the defined state space, transition intensities, 𝜇𝓍+𝓉
𝒿𝓀
, are inferred from the observed data 
and are the basis for all other output rates. These can be translated into transition 
probabilities, 𝑝𝓍
𝒾𝒿
𝓉 , that show, over longer time periods, how likely a patient is to transition 
from one state to another. The average length of time in a certain state before moving to 
another, the sojourn time, can also be calculated along with the total time spent in a state 
over a period. 
7.3.1 Transition intensities 
Without consideration for covariates, the estimates of transition intensities, 𝜇𝓍
𝒾𝒿
, are shown in 
Table 16 and Table 17, along with a 95% confidence interval. The final column is the force of 
mortality from each state. An interpretation of the rates is provided for each model. 
7.3.1.1 BMI model 
An individual who is Pre-obesity is 2.5 (0.015/0.06) times more likely to move to Obesity 1 
than Under/Normal BMI. Those in Obesity 1 and 2 are only a little more likely to lose weight 
than gain weight.  
7.3.1.2 HbA1c model 
An individual who has Good HbA1c is 2.5 (0.409/0.165) times more likely to move to Poor 
than Excellent HbA1c. Those with Poor control are almost equally likely to progress or 
regress. Those with Less than poor HbA1c are twice as likely to improve HbA1c control to 
Poor than progress to Very Poor. 
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Table 16: BMI model transition intensities 
State To      














(0.014, 0.016) - - 
0.001  
(0.001, 0.001) 






(0.009, 0.011) - 
0.000  
(0.000, 0.001) 
Obesity 2 - - 















Table 17: HbA1c model transition intensities 
State To      























(0.675, 0.788) - 
0.000  
(0.000, 0.003) 
Less than poor - - 
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7.3.2 Explanatory variable  
Neither model resulted in statistically significant difference in transition rates by IMD. The 
odds ratio, with 95% confidence interval, represents a comparison of the transition rates of 
the least deprived group to the baseline most deprived group. These are grouped into 
progression (worsening) or regression (improving) BMI and HbA1c states for interpretation 
for impactibility. 
7.3.2.1 BMI model 
The confidence interval for the odds ratio generally cross 1 as shown in Figure 24.  
Figure 24: BMI model - odds ratio of transition rates by IMD group 
 
7.3.2.2 HbA1c model 
The odds ratios significantly different to 1 in Figure 25 provide a mixed message; the least 
deprived group has lower transition intensities from Poor to Less than poor (higher 
impactibility), and lower transitions from Good to Excellent and Less than poor to Poor (lower 
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Figure 25: HbA1c model - odds ratio of transition rates by IMD group 
 
7.3.3 Transition probabilities 
Transition probability for 12- and 60-months periods are estimated. 
7.3.3.1 BMI model 
Table 18 shows that an individual with a BMI of Obesity 2 has a 72% chance of remaining in 
the same state in a 1-year period, compared to 10% of progressing to Obesity 3 and 16% 
chance of regressing to Obesity 1. 
Over a 5-year period the probabilities of BMI changing states are higher, as shown in Table 
19. For example, an individual with a BMI of Obesity 2 has a 32% chance of remaining in the 
same state over a 5-year period, compared to 20% of progressing to Obesity 3 and 44% 
chance of regressing to a lower BMI. 
Table 18: BMI model transition probabilities (expressed as %) - 12 months 












Under/Normal 80.8 15.5 1.4 0.1 0.0 2.3 
Pre-obesity 6.1 78.1  13.9 0.8 0.0 1.0 
Obesity 1 0.4 10.7 78.8 8.9 0.6 0.6 
Obesity 2 0.0 1.1 16.3 72.0 9.9 0.6 
Obesity 3 0.0 0.1 1.5 13.9 83.7 0.8 
Deceased - - - - - 100.0 
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Table 19: BMI model transition probabilities (expressed as %) - 60 months 












Under/Normal 39.5 34.0 14.3 2.5 0.4 9.3 
Pre-obesity 13.5 41.6  30.8 7.4 1.7 5.0 
Obesity 1 4.4 23.7 45.2 17.5 5.9 3.3 
Obesity 2 1.4 10.5 32.2 32.1 20.6 3.2 
Obesity 3 0.3 3.4 15.2 28.9 48.5 3.7 
Deceased - - - - - 100.0 
 
7.3.3.2 HbA1c model 
Table 20 shows that an individual having a Hba1c of Less than poor has a 19% chance of 
remaining in the same state in a 1-year period, compared to 27% of progressing to a worse 
HbA1c and 52% chance of regressing to better HbA1c. 
Table 20: HbA1c model transition probabilities (expressed as %) - 12 months 
 State To      






Excellent 57.2 17.4 8.3 9.1 7.3 0.7 
Good 36.3 18.9 11.3 15.3 17.6 0.6 
Poor 28.5 18.6 12.1 17.5 22.7 0.6 
Less than poor 22.4 18.0 12.5 19.1 27.4 0.6 
Very poor 13.8 16.0 12.5 21.2 35.8 0.7 
Deceased - - - -  100.0 
Over a 5-year period the probabilities of HbA1c improving are higher, as shown in Table 21.  
Table 21: HbA1c model transition probabilities (expressed %) - 60 months 
 State To      






Excellent 36.2 17.2 10.4 14.5 18.6 3.2 
Good 35.8 17.2 10.4 14.6 18.9 3.1 
Poor 35.6 17.2 10.5 14.7 19.0 3.1 
Less than poor 35.4 17.2 10.5 14.7 19.1 3.1 
Very poor 35.1 17.1 10.5 14.8 19.3 3.2 
Deceased - - - - - 100.0 
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7.3.4 Mean sojourn time 
Mean sojourn times show the average stay in a single state before transitioning to another 
and are provided with 95% confidence intervals.  
7.3.4.1 BMI model 
Table 22 shows that an individual diagnosed with T2DM with an Obesity 2 BMI is likely to 
remain in that state 2.8 years before transitioning. 
Table 22: BMI model - mean sojourn times in months with 95% confidence interval 
   95% CI 
State Estimate SE Lower  Upper  
Under/Normal 54.3  3.7  47.5 62.1 
Pre-obesity 44.9  1.6  41.8 48.2 
Obesity 1 45.6 1.4 43.0 48.4 
Obesity 2 33.9 1 31.9 35.9 
Obesity 3 63.5 2.6 58.6 68.9 
Deceased - - - - 
 
7.3.4.2 HbA1c model 
Table 23 shows that an individual who has a Very poor HbA1c is likely to remain in that state 
almost half a year before transitioning. 
Table 23: HbA1c model - mean sojourn times in months with 95% confidence interval 
   95% CI 
State Estimate SE Lower  Upper  
Excellent 12.6 0.3 12.1 13.1 
Good 1.7 0 1.7 1.8 
Poor 0.7 0 0.7 0.7 
Less than poor 1.3 0 1.3 1.4 
Very poor 5.5 0.1 5.3 5.8 
 
7.3.5 Total length of time 
The estimated total length of time spent in each state is forecasted for an individual over a 
60-month period. 
7.3.5.1 BMI model 
Table 24 shows that a Pre-obese individual is expected to have roughly half a year in 
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Table 24: BMI model - total length of time in months in a state - 60-months 












Under/Normal 38.0 14.6 3.8 0.5 0.1 3.1 
Pre-obesity 5.8 37.3  13.1 2.1 0.3 1.5 
Obesity 1 1.2 10.1 38.4 7.8 1.6 1.0 
Obesity 2 0.3 2.9 14.4 32.5 9.1 0.9 
Obesity 3 0.0 0.6 4.1 12.7 41.4 1.1 
Deceased - - - - - 60.0 
 
7.3.5.2 HbA1c model 
In Table 25, an individual with Poor HbA1c is expected to have roughly 1.5 years in 
Excellent, under 1 year in Good, just over half a year in Poor, under 1 year in Less than 
poor, and Very poor in a 5-year period. 
Table 25: HbA1c model - total length of time in months in a state - 60-months 
 State To      





Excellent  28.7   10.0   5.4   6.9   7.9   1.0  
Good  20.9   12.3   6.8   8.8   10.4   0.9  
Poor  18.6   11.1   7.6   10.0   11.8   0.9  
Less than poor  17.0   10.4   7.1   11.2   13.4   0.9  
Very poor  15.0   9.4   6.5   10.3   17.8   1.0  
Deceased  -     -     -     -     -     60.0  
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7.4 Accuracy 
The model is tested for its fit to the historic data using the training dataset and predictive 
accuracy using the validation dataset in an Expected vs Observed analysis.  
7.4.1 Fit to historic data 
The transition rates are used to generate expected transitions which are compared to the 
observed transitions in the training dataset.  
7.4.1.1 BMI model 
The BMI model fit to the historic data is fair until 50-months, as shown in Figure 26. The 
model is greatly underestimating the number of deaths (State 6) which is causing an 
overestimation in other states. 
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7.4.1.2 HbA1C model 
Similarly, the model is greatly underestimating the number of deaths (State 6), as shown in 
Figure 27. However, the model is also overestimating Excellent (State 1) and Very poor 
(State 5). A short-lived effect, i.e. durational, seen in Excellent and Very poor states is not 
being captured by the model26. 
Figure 27: HbA1c model Observed vs Expected - historic data 
 
 
7.4.2 Predictive accuracy 
The transition rates are used to generate expected transition based on the validation dataset 
and compared to the observed transitions. The impact of transition intensity inaccuracies 
accumulates over time causing the fit to deteriorate. 
 
 
26 Further interpretation is provided in the discussion in Section 8.2. 
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7.4.2.1 BMI model 
The predictive accuracy of the BMI model is fair at shorter time periods but is not useable 
after 4-years, as shown in Figure 28. The predictive accuracy for Under/Normal is poor due 
to lower data volumes. 
Figure 28: BMI model O/E ratio - predicted accuracy 
 
7.4.2.2 HbA1C model 
The predictive accuracy of the HbA1c model is poor at shorter time periods especially for the 
extreme ranges of HbA1c, as shown in Figure 29. 
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Chapter 8 Discussion 
8.1 Summary of findings 
Transition rates for BMI and HbA1c in the first 5-years of diagnosis for ages 40 to 49 
inclusive, under ‘current practice’ interventions, were modelled to assess impactibility using 
MSM. The model design has weaknesses impacting its accuracy but as a proof of concept 
for IM the choice of MSM is positive.  
MSM may be a useful tool for the purpose of IM for several reasons: it is suitable for the 
analysis routine health data; it can be used for multiple objectives which align to IM use, and; 
it provides insight into the time spent in different states from which impactibility can be 
inferred when related to cost or health status. 
This proof of concept model illustrates how some recommendations made in Chapter 4 could 
be applied in practice, namely clarity and awareness. 
The model design has been related to the PHM aims by linking the outcome of interest to 
BMI and HbA1c. Control of HbA1c is considered to reduce the impact of diabetes and risk of 
sequalae (71, 114) and BMI is a target of lifestyle interventions (114). Therefore, impactable 
people could be considered as those who: regress through states by decreasing BMI or 
HbA1c; or people who spend longer in healthier states such as lower BMI or controlled 
HbA1c states. 
Creating an impact on these measures would directly improve health status and, is indirectly 
assumed to reduce costs. The many sequalae of T2DM require high health service utilisation 
(4, 71, 114). The risk of sequalae are assumed to decrease with improved HbA1c and BMI 
(114, 140, 141) and therefore the utilisation and costs should reduce in proportion. This 
assumption is made explicitly and would need to be evaluated. 
Patient experience would require separate evaluation. 
A barrier to successful IM implementation is the concern regarding inequalities (27). This 
simplified model was not able to show that transition rates vary by IMD. However, it is not 
proposed that this is taken in evidence against these concerns but shows how a model can 
be created to assess if impactibility varies by variables associated with health inequalities 
during design and ongoing evaluation.  
Testing an explanatory variable is a step in deriving impactibility criteria. In this proof of 
concept, impactibility criteria were not derived however odd ratios produced by MSM can test 
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the significance of explanatory variables for that purpose. The same process could be used 
to monitor the consequences of chosen impactibility criteria on health inequalities. MSM can 
produce survival duration; a common clinical judgement impactibility criterion. 
The accuracy of IM using MSM can be evaluated using fit to historic data and predictive 
accuracy with observed vs expected analysis. The funnel of doubt in making predictions 
widens with time and therefore rates that more accurately account for the underlying process 
are preferred for long-term forecasts. 
It is important to establish that a model in its own right is neither ethical nor unethical, only 
the use of the outputs can be judged as such. A model may lend itself to highlight 
impactibility by variables that correlate to health inequalities, but it is the model user who 
decides how to implement the results. 
Impactibility assessed in terms of BMI, a modifiable risk factor, highlights the importance of 
earlier stages of prevention; as at an individual level the drivers of impactibility may be 
“highly resistant to change”(8)(p.249) as evidenced by the relative stationarity in the BMI 
process. For chronic diseases like T2DM there is a “need to look beyond simply providing 
medical care, toward services which address patients’ broader social and behavioural health 
needs” (79)(p.2018). The results of IM analysis could be used to promote and target earlier 
stages of prevention and work across the wider health system. For example, the age of NHS 
Health Check could be brought forward where there is a lack of impactibility. 
8.2 Strengths and limitations 
More complex modelling techniques have been suggest (142) but there is a place for MSM 
when producing insights to work across the wider health system. The strengths and 
limitations of this proof of concept are considered in terms of the data and study design. 
8.2.1 Data 
The SCI database is of good quality but is not timely with insights 3-years lagged. IM must 
overcome data time lags to produce actionable predictions. 
For this case study, the outcome of interest was available in the data with good coverage 
and quality. However, the scope of IM may be limited to use cases where health outcome 
data pre-exists. 
The dataset created for this proof of concept was minimally defined however increased 
linkage and additional variables could increase the actionable impactibility insights. The data 
will only ever represent an impression of a person and will be missing many important 
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variables (80). For example, ethnicity was not well populated in the dataset and work was 
not undertaken to link social factors. 
8.2.2 Study design  
The study design can be assessed by the state space, transition intensity matrix, cohort and 
explanatory variable test. 
8.2.2.1 State space and transition intensity matrix 
A balance between the number of states and credibility of results is an important model 
choice (143). Defining a 6-state space for HbA1c and BMI provides increased granularity to 
assess impactibility.  
However, for lower data volumes in the Under/Normal category influenced the accuracy of 
the BMI model estimates. To improve accuracy in the future, Under/Normal could be 
grouped with Pre-obesity. 
Goel et al. recently published a MSM for T2DM using a 3-state mode27 (144). This model is 
simplified in comparison; however, the main conclusion is that that after diagnosis most time 
is spent with HbA1c above 6.4% which is less informative for impactibility to translate into 
action. 
The transition matrices have been defined so that observed movements from State 1 to 3 
must transition via State 2. Setting illogical instantaneous transitions to zero is not always 
adopted (144) but is a strength as the model solves for rates more closely representing the 
underlying process.  
An equivalent force of mortality to the model data would be approximately 0.002 based on 
the Scottish population (129). In comparison, the transition rates in the final column of Table 
16 and Table 17, appear low. This discrepancy is seen in the inaccuracy in Figure 26 and 
Figure 27. The lack of credible data for transitions to deceased warrants using a transition 
intensity offsets based on a relevant population or T2DM mortality table (145). 
This would improve the fit for the BMI model over time; by absorbing lives in the deceased 
state the overestimates in others would be reduced at longer time periods. A similar 
 
 
27  The 3 states are defined as: HbA1c ≤5.6% as Normal, ≤6.4% as Pre-diabetic and >6.4% 
as Diabetic 
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improvement would occur for the HbA1c model however, it would not correct its inaccuracy 
at earlier time periods. 
8.2.2.2 Cohort 
The cohort is defined to remove the impact of confounders however, it is clear from the 
results of the HbA1c model that the assumption regarding duration is not fit for purpose. The 
inaccuracy seen in the Excellent and Very poor HbA1c states suggests a durational affect is 
present in the process. The dataset has more observations in year 1 of diagnosis than any 
other and as such transition rates are influenced by shorter durations which do not appear to 
be indicative of later durations. A duration-based variable is required in the model design.  
8.2.2.3 Explanatory variable test 
Having only two IMD groups to compare the most to the least deprived IMD deciles may bias 
the result toward the null. An improved test may compare the least deprived 30% to the most 
deprived 30% of IMD scores. However, a reduced amount of data in each sub-group may 
widen confidence intervals for the odds ratio. 
8.3 Implications 
This research has implications for future research and for stakeholders in the health and 
social care system and wider health system. 
8.3.1 Future research 
There is much that can be done to improve this proof of concept including: use of mortality 
rate offset, introducing duration, and validating or developing beyond the simplifying 
assumption28.  
A next step is to compare transition rates for those who complete the T2DM education 
programme, Desmond, to those who did not (146)29. This will illustrate the usefulness of 
MSM for intervention effectiveness evaluate. 
This dissertation furthers the areas of clarity and awareness but has not extended 
collaboration or preparedness. A summary of a self and group-reflective exercise, which 
expands on collaboration and awareness, designed and piloted during this project is 
 
 
28 The proof of concept simplifying assumptions were described in Chapter 6 and are 
summarised in Appendix 10. 
29 Data access for research purposes has been agreed with Imperial College Health Partners 
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provided in Appendix 12. An evaluation plan is still required and an agreement on an ethical 
framework30. 
8.3.2 Clinical practice, public health policy and practice 
PHM requires a closer collaboration between clinical and public health practice to develop 
agile solutions to the dynamic problem of optimising health under constraints across the 
wider health system. Two aspects will be relevant immediately; culture and data. 
The culture of working in an LHS will need to be established to gain the collaboration that is 
key to PHM’s success as an agile solution (27, 60). This collaboration is developing in the 
UK however, to be successful a clear link between IM and the common strategic objectives 
must be established (27); to optimising health under constraints. The ethos of IM could be 
used when facilitating communications between various stakeholders about the objectives of 
IM. 
Leveraging data insights is crucial to PHM and an LHS (27, 60, 76). To create an agile 
solution, IM must live within an LHS which “require[s] greater alignment between the analysis 
and decisions taken; between analysts and the people interested in data quality 
improvement; and between the analysis and public attitudes regarding appropriate use of 
data”(80). The first step at the local level may be to ensure data infrastructure, knowledge, 
and quality are adequate (27, 57, 60, 80). Equally important is managing public expectations 
regarding the use of anonymised data to improve population health (57, 60, 80). The use of 
health data is a politically sensitive topic and it is therefore crucial to establish the objectives 
of IM; to optimise health under constraints.  
 
 
30 An ethical framework is under development by the working party and academics. 
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Chapter 9 Conclusion 
The sustainability pressures faced by the health systems today will not be the same in the 
future. To ensure the long-term viability of Universal Health Care provision, agile solutions 
are being designed to navigate the dynamic problem of optimising health under constraints. 
IM is a new development in PHM which seeks the greatest increase in population health, 
patient experience, and reduction in health inequalities for the cost incurred.  
It is important to develop and apply IM as an agile solution, so that it may be successful in 
accommodating the changing nature of the optimisation problem. This dissertation has 
provided insights in that direction at this early stage of IM development. 
There is a cautious yet optimistic view in the literature of IM’s ability to achieve the PHM 
aims and navigate health system sustainability. Practical recommendations for IM’s 
development and application have been distilled into an ethos of IM; awareness, clarity, 
collaboration, preparedness and working across a wider health system. A proof of concept 
has shown how recommendations can be applied in practice and makes a case for MSM as 
useful for IM. 
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Appendix 2. The PHM Working Party 
Further details on the Institute and Faculty of Actuaries PHM working party can be found in 
the link below. 
https://www.actuaries.org.uk/practice-areas/health-and-care/research-working-
parties/population-health-management 
Working members names, positions, and institutions are listed below.  
Table 26: Population Health Management Working Party membership 
Names  Position Institution 
Alpesh Shah Actuary, Chair PwC 
David Beddows Actuary, Deputy 
Chair 
Optum Health Solutions 
Chris Bull Actuary Government Actuary’s Department 
Dr Illyas Bakbergenuly Actuary University of East Anglia 
Mark Flint Actuary SCOR 
B6654040 Actuary University of Edinburgh 
Mei Sum Chan Actuary University of Oxford 
Craig Swatton Actuary Swiss Re 
John Seymour Actuary  PwC 
James Umpleby Senior Analytical 
Manager 
NHS England 
Tanya Hayward Actuary Milliman 
Joanna Buckle Actuary Milliman 
Dr Sarah Culkin Data policy NHS England 
Mohamed Elsheemy Actuary NHS England 
Stephen Lorrimer Head of Analysis & 
Insight 
NHS England 
Dr Chris Martin Head of Modelling Crystallise 
Dr Thomas Mason - NHS England 




Lisa Morgan Actuary International Labour Organisation, 
WHO 
Dr Carlos Jackson Chief Data & 
Analytics Officer 
Community Care of North Carolina 
Andi Orlowski Health Economist Imperial College Health Partners 
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Appendix 3. Creating a distinction in the IM 
proposals 
There is a distinction within the proposals in Table 2, Section 4.2.2.2, that is not clearly 
established in the literature. Data analytics can be leveraged in a PHM system to highlight 
unwarranted variation in service provision and utilisation (10). Proposal 4 involves 
opportunity analysis to improve quality by finding duplication or gaps in care (10, 22, 25).  
Analysis of data that highlights lives currently not receiving the required interventions, i.e. 
under-provision, or receiving more intervention than necessary, i.e. over provision, would 
result in action to navigate towards adequate and appropriate provision. These actions 
thereby improve the timely and equitable delivery of care (25). Optimising health within the 
health and social care system, using these IoM’s quality of care dimensions (12), is a sub-
component of the wider health system PHM aims, as discussed in Chapter 2. Closing gaps 
in care works toward the PHM aims (28) but not, as argued here, for the objective of IM. This 
is because understanding why lives are not provided with required interventions provides 
reflection on the quality in the delivery of services, not a reflection on the impact created by 
the delivery of quality services.  
This distinction is emphasised when considering the resulting action when services are not 
delivered to high quality vs the action taken when the delivery of quality services does not 
create an impact. Poor quality delivery of care in primary and community settings is 
considered to increase care in hospitals for Ambulatory Care Sensitive Condition (‘ACSC’) 
(22, 25). Actions to improve the delivery of care include Audit and Feedback practices where 
regular monitoring seeks closer adherence to intervention guidelines i.e. the delivery of 
required interventions (147, 148). Financial incentives based on audit outcomes are used to 
incentivise the continuous improvement in provision, to navigate toward an appropriate and 
adequate provision of care. For example, diabetes is an ACSC and financial remuneration 
under Quality and Outcomes Framework (‘QOF’) is used to improve the provision of care 
(131).  
Table 27 shows that the actions taken when there are service delivery issues result in 
actions that navigate to an appropriate and adequate provision. At this stage, impactibility 
can be assessed. Under proposal 4, gap analysis  variation in utilisation and propensity to 




82  Appendix 3 
Table 27: Recommended action by delivery category 
Delivery Action Navigating 
Poor provision 
 
Poor quality services are delivered 
Improve quality dimensions: 





Good quality services that are under 
delivered 
Improve quality dimensions of 
timely and equitable 
Appropriate and adequate provision 
 





Good quality services that are over 
delivered 
Improve quality dimensions of 
efficiency 
 
Closing gaps in care, after a gap analysis, or prioritising gaps in care with a larger variation 
or health importance, after a weighted gap analysis, are actions undertaken to rectify 
delivery issues. In addition, analysis to avoid triple fail events31 (22) seek to improve the 
safe, effective and patient-centred dimension of quality care (12, 28). That is, to navigate 
away from poor-provision to adequate and appropriate provision. 
Analysis to understand variability in utilisation such as low-risk lives with high utilisation or 
high-risk lives with low utilisation are more nuanced. Variability in utilisation may be an 
indication of intervention delivery issues or an indication of patient preferences (25), as 
shown in Table 28. An understanding of what drives the variability will guide the resulting 
action. Where the variation is due to delivery issues, the action would navigate toward 
adequate and appropriate provision. Where the variation is due to patient preferences, IM 
would be warranted to understand the risk and impactibility drivers to tailor resources 
according to patient preferences, discussed in Section 4.2.3.2. 





High Expected Patient preference 
Under provision 
Low Patient preference Expected 
Over provision 
Propensity to benefit scores are based on analysis that assesses how far an individual’s 
health status is from those resulting from following care guideline recommendations (71). 
This model assumes an intervention has a full impact and need only be provided to improve 
health status. This model does not analyse impactibility but assumes all lives have full scope 
 
 
31 Triple fail events are where care does not improve health, is not patient-cantered, and 
does so at a cost. 
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to benefit given adequate and appropriate provision. The resulting action is therefore to 
navigate toward adequate and appropriate provision. 
It is argued here, that IM should analyse if an intervention creates an impact where there is 
appropriate and adequate provision of care. Therefore, although similar to IM, proposals 
based on service provision or utilisation that result in action to navigate toward adequate and 
appropriate provision are not progressed in this dissertation. It is argued here that these do 
not meet the IM objective in the working definition (43).  
Focusing on IM proposals that only consider the optimisation problem within the health and 
social care system instead of the wider health system, would hinder potential of IM to be 
developed an agile solution adaptive the dynamic nature of the problem. Similarly, proposals 
where the aims are limited to the 6 dimensions of quality care instead of the PHM aims, 
works to limit the potential solutions to those of service delivery and utilisation instead of  
creating structural health system changes in the wider health system to accommodate the 
dynamic problem. 

  Impactibility modelling 
 
Appendix 4   85 
 
Appendix 4. Literature search 
Alternative terminology 
Within health economics the concept of priority-setting and rationing are relevant. Selecting 
patients with the greatest return on investment (‘ROI’) is considered under patient selection 
rationing (45).  
Clinical judgement and decision-making are practical elements of medical practice. The 
topics of triage and case-finding helped contextualise the development of decision-making 
aids and the ethical considerations of IM (46). 
Precision medicine is "an emerging approach for disease treatment and prevention that 
takes into account individual variability in genes, environment, and lifestyle for each person" 
to identify an effective approach (47). Genomics and pharmacogenomics (113) were not 
considered further as routine population data is not available for analysis. Finding an 
intervention that is beneficial to a patient’s health given their characteristics was considered 
further. 
References by relevance 
To increase transparency of the literature search, a list of references by relevance grading is 
provided in Table 29 and a list of excluded citations. 
Table 29: Relevance grading - with references 
Second review: Full body text References 
Low – background information 
 
37 sources 
(16, 32-34, 44-47, 50, 54, 55, 58, 61-63, 
68-70, 77, 81, 83, 84, 88, 89, 94-96, 101-
106, 111, 113, 149, 150) 
Medium – related to wider context 
26 sources 
(7, 23, 27, 31, 35, 41, 49, 51, 57, 59, 60, 
65, 79, 80, 82, 85-87, 90, 97, 98, 107, 
142, 148, 151) 




(8, 22, 25, 26, 28, 44, 52, 53, 56, 67, 71-
76, 78, 91, 152) 
 
Excluded citations 
Citations that were deemed not relevant are shown below for transparency. 
ACADEMYHEALTH. 2008. 2008 HSR Impact Awardee: Risk-Baed Predictive Modeling - 
Improving the Financing and Delivery of Health Care with Risk-Based Predictive 
Modeling [Online]. Washington, USA: Academy Health. Available: 
https://www.academyhealth.org/sites/default/files/risk-basedpredictivemodeling.pdf 
[Accessed 01 June 2019]. 
ALLAUDEEN, N., SCHNIPPER, J. L., ORAV, E. J., WACHTER, R. M. & VIDYARTHI, A. R. 
2011. Inability of providers to predict unplanned readmissions. Journal of general 
internal medicine, 26, 771-776. 
AN IHI TRIPLE AIM COLLABORATIVE 2015. Better Health and Lower Costs for Patients 
With Complex Needs. 
AUBERT, C. E., SCHNIPPER, J. L., WILLIAMS, M. V., ROBINSON, E. J., ZIMLICHMAN, E., 
VASILEVSKIS, E. E., KRIPALANI, S., METLAY, J. P., WALLINGTON, T. & 
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Appendix 5. Primary research for criteria 
derivation 
Primary research may be required to derive impactibility criteria to better tailor resources to 
achieve the PHM aims (44, 79, 82-84).  
Data can be collected, quantitatively and qualitatively, and combined from multiple 
stakeholders across multiple organisations to derive impactibility criteria (151). Data 
collected directly from patients is seen as crucial to find suitable interventions to tackle the 
wider determinants of health (79, 82, 149). In addition, data direct from patients is seen as 
useful where patient behaviour plays a role in managing the outcome of interest (13, 44, 75, 
84, 87, 89). This is because understanding the drivers of former non-compliance, 
disenrollment or unwillingness to participate in an intervention could help tailor the 
intervention (25, 53). Measures of patient activation or engagement could be tested as 
explanatory factors for impactibility (25, 85, 86). The actions resulting may be to tailor 
interventions to first improve patient engagement (25, 75, 79, 84, 88) using behavioural 
economics (13) or change theory (75, 87) as part of better managing the outcome of interest. 
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Appendix 6. Possible interventions: stages of 
prevention 
Intervention can be provided at different stages of disease progression to prevent an 
adverse health outcome. The range of downstream to upstream interventions can be 
described as four prevention stages (92, 93), shown in Figure 30. References to 
interventions in the literature are summarised under each stage. 
Figure 30: Intervention stages at each level of prevention 
 
Based on Disease prevention: a critical toolkit (93)(p.11) 
Tertiary prevention 
Where a disease has occurred and is symptomatic, interventions can be considered tertiary 
prevention (92). In the literature, the improved management of patients with established 
disease is anticipated to achieve the PHM aims (16, 26, 52, 94, 95). In the UK, these include 
case management, self-management programmes, and altering the location of care delivery 
(4, 8, 24, 33, 34, 96). 
Secondary prevention 
Where a disease is detectable but asymptomatic interventions are referred to as secondary 
prevention (92, 93). Population wide screening is an action which aims to provide 
interventions earlier to improve health status at a reduced cost i.e. two of the PHM aims. In 
the UK, this includes national cancer screening programmes and the NHS Health Check, 
which provides free screening every 5 years from age 40 to 74 for chronic conditions 
including diabetes (117). 
Primary prevention 
Although there is always a risk of disease in a population, some are more at-risk than others 
(92). Primary prevention seeks the detection of risk factors for future disease and the 
management of modifiable risk factors include diet and physical activity (92, 93). The NHS 
Health Check provides advice on modifiable risk factor management to reduce disease risk 
(117). 
The literature highlights the need to consider, at an individual level, the contributors to risk 
and impactibility such as housing, transportation, financial stressors, and behavioural 
aspects including medication adherence, exercise, diet, and substance use and abuse 
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Primordial prevention 
At a primordial prevention stage, actions are focussed on the wider health system which 
enables risk factors for disease to be high or increasing in prevalence in society (92, 93). In 
the UK, examples include public smoking bans, minimum unit alcohol pricing and sugar 
sweetened beverage tax.  
Stokes et al. stresses the importance of recognising social factors that drive risk and 
impactibility, noting that these are “multifaceted, deeply ingrained and linked to the wider 
social context, and therefore highly resistant to change” at an individual level (8)(p.249).  
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Appendix 7. Testing predictive model accuracy 
To test predictive model accuracy, measures such as areas under the receiver curve, c-
statistic, sensitivity, positive predictive value, r-squared and observed vs. expected analysis 
are evident in the literature. A summary of these is provided here for ease of reference to IM 
developers. 
The area under the receiver operating characteristics (‘ROC’) curve is used to portray model 
accuracy (25) alongside the c-statistic (68). The C-statistic uses the distribution of true 
positives and true negatives across the model output (24). However, for PM to be beneficial 
in a PHM system, the benefits of using it must outweigh the costs (24) which usually gives 
rise to a chosen cut-off for the level of risk or impact deemed worth intervention (24). Where 
only the accuracy beyond the chosen cut-off is required, measures of sensitivity and positive 
predictive value are useful (24), as shown in Table 30. 
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Based on text from Lewis (24) 
The r-squared (‘R2’) value is an appropriate measure of predictive accuracy at an individual 
level; representing the “total variation among individual observations that could be explained 
by the model” (59)(p.157). However, at a grouped level, a predictive ratio like observed vs 
expected (O/E) is more appropriate (59). 
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Appendix 8. Working description of MSM 
theory 
A working description of MSM theory is provided here but full explanation can be found in 
MSM textbooks (118, 119). 
An individual’s life history is considered as “represented by time spent in states and 
movement between states” (119) (p.256). An individual can occupy one of the possible“ 
‘states’ at any given time and moves between states at random times governed by the 
probabilistic model” (119) (p.xv). Therefore, to specify a mathematical model of the life 
history, a state space and transition intensities are required (119)( p.257). 
State space 
The state space describes the collection of states possible for an individual to occupy at any 
particular time (119)(p.256). Figure 31 shows a MSM with transient states 0 and 1, with a 
means of exit, and an absorbing state 2, with no possible means of exit (118). 
Figure 31: State space example 
 
Adapted from Modelling Mortality with Actuarial Applications textbook (119) (p.258) 
It should be possible to determine the state occupied by an individual at a given time. It is the 
modeller’s choice to define meaningful states “that allow the objective of modelling and 
analysis to be met” (118)(p.2). In practice, the number of states is often reduced for model 
parsimony. A balance between the number of states, the information available in the data 
and the credibility of results is also a model choice (143).  
In general, there can be M+1 states considered for the 𝒾𝑡ℎ of 𝓃 individuals in a population. 
Transitions between these states are counted. For each pair 𝒿 ≠ 𝓀 of state labels, 𝒩𝒾
𝒿𝓀(𝓉) is 
defined to be the number of transition from state 𝒿 to state 𝓀 made by the 𝒾𝑡ℎ individual 
(119)( p.257). A counting process is established based on the observed “number and times 
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Transition intensity 
Transition intensities between states define the model. These are the forces to which an 
individual is subject; keeping the individual in the current state or transitioning to another 
state. 
In Figure 31, the arrows indicate possible transitions: 
- It is possible to transition from state 0 to 1, state 1 to 0, state 0 to 2, state 1 to 2, with 
the relevant transition intensity at age 𝓍 + 𝓉 denoted by 𝜇𝓍+𝓉
𝒿𝓀
 
- It is not possible to transition from state 2 to 0, or state 2 to 1 so no arrows are 
shown i.e. the transition intensity is set to zero, 𝜇𝓍+𝓉
20  =  𝜇𝓍+𝓉
21 = 0 
A transition intensity matrix, shown below, has rows that indicate the state held and columns 
the potential transition state and contains all transition intensity rates. 
Equation 2: Transition intensity matrix 

































Transitions not allowed in the process between pairs of states should have transition 
intensities set to zero in the matrix, for example returning from deceased to healthy. 
Otherwise, transition intensities are inferred from suitable life history data; that is, data 
containing “transitions between pairs of states at random times” (119)( p.xv). Transition 
intensities can depend on covariates which act in a multiplicative or additive fashion 
(118)(p.9). 
Transition intensities are defined below and are linked to transition probabilities. 
- For 𝒾 ≠ 𝒿, over a small 𝒹𝓉 then 𝜇𝓍+𝓉
𝒾𝒿
 is defined to be the transition intensity from 










Transition probabilities follow on from transition intensities as “𝓟(𝓉) can be calculated by 
taking the matrix exponential of the scaled transition intensity matrix” (134)(p.6). 
The transition probability matrix, shown below, has rows that indicate the state held and 
columns the potential transition state.  
Equation 3: Transition probability matrix 
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Transition probabilities are defined as: 
- 𝑝𝓍
𝒾𝒿
𝓉  is the probability that an individual in state 𝒾 at age 𝓍 will be in state 𝒿 at age 
𝓍 + 𝓉 
- 𝑝𝓍
𝒾𝒾
𝓉  is the probability that an individual in state 𝒾 at age 𝓍 will be in state 𝒾 at age 
𝓍 + 𝓉, noting that this does not require stationarity in state 𝒾 
- 𝑝𝓍
𝒾𝒾
𝓉 is the probability that an individual in state 𝒾 at age 𝓍 will remain in state 𝒾 until 
at least age 𝓍 + 𝓉 (known as occupancy probability) 
Counting Process, Indicator Function and Martingale 
Fitting a parametric model to complete life history data has similarities to likelihood in 
Poisson distribution, Poi(𝜆). Each event is counted over a period of time where “a transition 
from one state to another can be considered as a type of event” (118)(p.2).  
An indicator function, 𝑌𝒿
𝒾(𝓉), is used to specify the life history in terms of a counting process 
used to generate transition intensities, 𝜇𝓍+𝓉
𝒾𝒿
 . The indicator function has martingale properties 
such that all information prior to time 𝓉 is included at time, 𝓉, in the current state, satisfying 
the Markov property which simplifies the mathematics (see (118, 119) for further 
information). 
Once the counting process is defined, inference can be made from the observed data.  
Alive-Dead Model 
A familiar example of Poisson counting process can be represented in a MSM model. For a 
Poisson GLM analysis of mortality rates, µx, the model requires the time of exposure to risk 
of death and the number of deaths in the period, counted as occurring, 1 or not, 0. This 
count is similar to the indicator used in the MSM model and the time period between 
observations as the exposure to risk.  
Just as Poisson GLM provides an instantaneous force of mortality, the MSM provides an 
instantaneous transition intensity represented as:  𝜇𝑥+𝑡
𝐴𝐷  
The transition intensity for a two state, alive-dead, model would provide force of mortality µx+t 
for a give age x. Deceased here would be an absorbing state as no life can return from dead 
to alive. This is represented in the state space in Figure 32 with a one directional arrow to 
Dead, without a returning arrow. 
Figure 32: Alive-dead state space 
 




98  Appendix 8 
The Alive state, in the timeline shown in Figure 33, can be broken down further into multiple 
states which gives rise to a multi-state model. 
Figure 33: Life event timeline 
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Appendix 9. MSM data frame example 
A data frame is prepared to the msm R package input requirements of a counting process 
format; each row is an event that shows “the time of the observation and the observed state 
of the process” (134)(p.15). 
An example data frame for the model is provided below. Time is accumulative in months. 
IMD deciles from the data are grouped; group 1 is the most deprived with IMD deciles [1,5] 
and group 2 is the least deprived with IMD deciles [6,10]. 
Table 31: Example data frame 
Unique ID 
anonymised 
State Time  
Months 
Explanatory variable 
IMD group (1 or 2) 
𝒾 1 0 1 
𝒾 2 2.5 1 
𝒾 2 5 1 
𝒾 + 1 1 0 2 
𝒾 + 1 4 4.5 2 
⋮ ⋮ ⋮ ⋮ 
⋮ ⋮ ⋮ ⋮ 
𝓃 1 0 1 
𝓃 2 1 1 
𝓃 6 5 1 
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Appendix 10. Summary of simplifying 
assumptions 
Simplification made, in the spirit of a proof of concept and for model parsimony, are 
summarised in Table 32. These would need validation before developing the model beyond 
a proof of concept. 
Table 32: Summary of simplifying assumptions 
Area Assumption 
Age Assumed to be no material change in transition rates in 10-year 
age range 
Morbidities Low prevalence in age at diagnosis [40,49] 
No material variation between IMD groups. 
Duration Assumed to be no material change in transition rates in 5-year 
period after diagnosis 
Intervention A range of guideline interventions used in the first 5 years of 
diagnosis can be analysed under ‘current practice’.  
No material variation in intervention use between IMD groups. 
Selection bias Assumed to be limited 
 
There is considered to be no bias in the lives missing HbA1c or 
BMI from there medical records. 
 
Those with one event in a 5-year period are not assumed to be 
inherently different to all lives. 
Follow up bias Assumed to be limited 
 
No material forms of exit other than death 
 
Missing data The provision of private health care for chronic disease is 
considered not to be material. 
 
The removal of data with missing postcodes is not considered 
to introduce bias. 
Confounders The variation by IMD group for gender, age, duration and 
morbidity are not material. 
 
Smoking does not impact BMI or HbA1c control. 
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Appendix 11. Additional results 
 
Number of observations 
Figure 34 shows the similar distribution of observations by IMD group in the full dataset for 
both models. 
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Data summary - BMI 
From the BMI training dataset the movements of the most and least deprived IMD groups 
are provided in Table 33 and Table 34. 
Table 33: BMI observed transitions - most deprived IMD group 












Under/Normal 1148 101 1 0 0 18 
Pre-obesity 122 3038 298 1 0 23 
Obesity 1 1 375 4944 328 1 21 
Obesity 2 1 1 455 4224 254 17 
Obesity 3 0 0 7 358 4932 20 
Deceased 0 0 0 0 0 0 
Table 34: BMI observed transitions - least deprived IMD group 












Under/Normal 852 86 1 0 0 7 
Pre-obesity 103 1893 212 0 0 12 
Obesity 1 1 239 3052 189 0 10 
Obesity 2 0 1 245 2090 149 6 
Obesity 3 0 0 1 202 2327 9 
Deceased 0 0 0 0 0 0 
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Data summary – HbA1c 
From the HbA1c training dataset the movements of the most and least deprived IMD groups 
are provided in Table 35 and Table 36. 
Table 35: HbA1c observed transitions - most deprived IMD group 
 State To      





Excellent 6,694 1,390 409 324 259 28 
Good 1,395 1,958 919 752 497 10 
Poor 459 794 878 866 561 11 
Less than poor 519 813 938 1,953 1,359 12 
Very poor 510 594 627 1,821 6,646 39 
Deceased - - - - - - 
 
Table 36: HbA1c observed transitions - least deprived IMD group 
 State To      





Excellent 3,886 842 244 169 115 19 
Good 838 1,303 537 465 265 10 
Poor 256 514 555 523 270 1 
Less than poor 242 495 533 1,213 832 7 
Very poor 284 341 342 1,084 3,477 11 
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Fit to historic data 
The impact of inaccuracies in the transition rates accumulates over a longer time period 
causing the model fit to deteriorate with time as can be seen for both historic data fit for BMI 
and HbA1c. 
BMI 
A ratio comparison of observed to expected occupancy in each state is shown in Figure 35. 
The model fit deteriorates with time. The fit is poorest for Under/Normal which has a lower 
amount of data and so poorer accuracy in the fit to historic data. 
Figure 35: BMI model O/E ratio - historic data 
 
HbA1c 
The inaccuracy of the model for the short-lived affect within year 1 for Excellent and Very 
poor is clear, in Figure 36. 
Figure 36: HbA1c model O/E ratio  - historic data 
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Appendix 12. A collaboration and awareness 
exercise 
Collaboration and awareness are an important element of IM. As a first step, in this direction 
I created an exercise to capture my own values and beliefs in a self-reflective exercise. An 
opportunity arose to pilot this within a group setting and the process developed is shared 
here and in the working party’s first output (43)32 
When building, choosing, parameterising and using a model there are many choices faced 
by the user. The decision-making process is informed by prior experiences, values and 
beliefs. These elements can either be consciously or unconsciously embedded into a model. 
I thought it was important to take time to reflect on the nature of my views and how they may 
differ from others. A means was sought to bring awareness to prior experiences, values and 
belief that frame my actions and decisions. The consequences desired and undesired of 
impactibility, and of wider population health management, were considered in a self-
reflective exercise. An opportunity to pilot this as a group exercise was presented by the 
working party which enhanced my understanding and expand my consideration further.  
Reflexivity is “the conscious examination of past experiences, thoughts and ways of doing 
things”(153). I considered this an important element of model development in a health 
context as it “challenges the status quo of practice, thoughts and assumptions”(153).   
Neneh Rowa-Dewar, a qualitative researcher at the University of Edinburgh, was consulted 
on if previous examples or a framework was available for this exercise. Neneh kindly 
directed me to the University of Edinburgh’s online Reflection Toolkit (153). After reviewing 
different methods, an initial attempt at a self- and group-reflection exercise was piloted with 
the Working Party. An example of the exercise and practical guidance is shared here so 
others developing IM may consider a process like this, for the benefit of collaboration and 
awareness.  
This process seeks to: 
• “Increase/improve performance and skills; 
• Increase awareness of ability and attribute and provide evidence for these; 
• Evaluate the quality and success of action plans; and, 
• Apply theoretical knowledge/frameworks to real experiences to expand understanding of 
underlying theory” (153) 
This was considered important to evidence: 
• conscious consideration for professionalism; 
• conscious consideration for multiple stakeholder views; 
• responsible and ethical use of modelling in a health context;  
• reflection on awareness and availability of ethics support; and,  
• ethical consideration for public health issues including health inequalities. 
The following learnings resulted from the group pilot:  
 
 
32 The output is not yet published. This work was undertaken by the author alone and the 
process was piloted in the working party group setting. 
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• Sufficient time should be allowed for self (min 1.5 hours) and group (min 2.5 hours) 
reflection as allowing discussions time to unfold creates fruitful learning 
opportunities; 
• A format should be provided where all in the group feel comfortable contributing to 
discussions with consideration for group size and independent/experienced 
facilitators  
• A wide range of valid views highlighted the complexity within health modelling and 
the need for clarity and transparency; 
• A structured process was helpful in navigating reflection within a group environment.  
Summary  
The following are shared with IM developers as areas that were considered essential and 
recommended in this exercise. 
Essential to do: 
• create time early in on in project management of model development to discuss 
reflection, the appetite to undertake reflection and agree a framework to undertaken 
reflection 
• discuss how reflection may benefit the outcome of the project, create a plan and 
allocate time accordingly 
Recommendation 
• pilot a self-reflection exercise ensuring that actions and improvement are the key 
outcome 
• pilot a group reflection exercise with a facilitator, record a summary of discussions 
and actions and improvements 
• create a plan of how actions and improvement will be further embedded into work 
Template Reflexive Exercise Process 
A template reflexive exercise is shared based on the work undertaken. Steps in the process 
may involve: 
1. Complete a self-reflexive exercise an example structure is provide below. The 
exercise may take 1 hour to complete, with individuals encouraged to write answers 
down to encourage self-reflection. Answers are not shared or seen by anyone other 
than the individual. Being open, honest and transparent when answering is 
beneficial. There are no right or wrong answers. The exercise is designed to provoke 
thought, i.e. reflection. Times were allocated next to each question as a guide for the 
participant, but it is up to the individual how much time to spend considering each 
question. 
2. Following 1, a group discussion was held. This is an opportunity to discuss the 
exercise and the experience as a group. Group-reflection was undertaken to 
increase the working knowledge in the group and to gain an appreciation and learn 
from others reflection experiences. It is important to establish with the group that not 
knowing or having answer to the self-reflection questions in 1 is ok; the learning is 
taken from the process of reflecting on the questions. 
3. Follow the group exercise, major themes from the discussion can be circulated to 
the group. Areas not captured in the group discussion that members believe 
important can be facilitated through an anonymous survey platform. Actions, agreed 
within the group, that resulted from the discussion should be created to increase and 
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improve understanding and awareness. These actions could be set at an individual, 
sub-group, or group level in a modelling or a separate project team.  
 
Self-reflexive Exercise 
Questions for the self-reflexive exercises were drafted. The nature of the items will depend 
on the nature of the work and the group. Sample questions have been provided but the user 
can create alternative prompts for reflection. 
1. Background 
a. The demographic profile of the group was reflected upon using an 
anonymous survey. This helped to understand the composition of the group 
better. Primary data collection requires due consideration of GDPR. 
b. An ethics resource survey was created to understand how comfortable 
members of the group were with making ethics-based decisions and if 
support resources were available to the group.  
2. Health 
a. Questions regarding health were posed to individuals to consider and for the 
group to reflect on. 







a. Questions regarding impactibility were posed to individuals to consider and 
for the group to reflect on. 





4. Ethic scenarios 
a. Three discussion scenarios were generated for individuals to consider and for 
the group to reflect on. 
b. One of the example scenarios is provided below: 
 
 
• How would you define health? 
• What is a strength of the WHO definition for health(1)? What is a 
weakness? How does your definition compare? 
• What does a holistic view of health mean to you? 
• What are some determinants of health? For you, your family, you 
colleagues and patients? 
 
• What does an impact to your health look like to you?  
• What does ‘creating an impact to health’ mean to you as a professional? 
• What does ‘impacting the populations’ health’ look like? 
• What do you believe currently creates an impact on population health? 













5. Stakeholders and perspectives 
a. Individuals were asked to consider different stakeholders and perspectives 
during the exercise. 
 
Group-reflexive Exercise 
A facilitator may be required for the group exercise. This could be a member of the group or 
an independent person with qualitative research experience such as focus groups. 
This is stage sought to establish actions resulting from the reflective exercises.  
1. Ground rules were established for group exercise: 
a. There are no right or wrong answers. Full respect for peer input, values and 
comments. Never feel forced to share anything you are uncomfortable with 
and please be respectful of others’ boundaries when sharing. No comments 
will be attributed to any person and to support open discussions Chatham 
House Rules are in effect.  
b. “It’s only reflection if it strives toward a better understanding”(153). The 
questions posed to the group are to help reflection on why others may have 
different perspectives of the same experience of the self-reflective exercise.  
c. The objective is to find purposeful examination of thoughts and practice 
2. Group reflection on background 
a. Questions were posed to the group regarding the outcome of the background 







Smoking has been banned in public places as second-hand smoke is detrimental 
to health. Taxes are imposed on tobacco with the aim of reducing consumption. 
Similarly, taxes are imposed on alcohol to reduce consumption. 
• How is Minimum Unit Pricing of alcohol similar or different to tobacco? 
• Reflecting on tobacco and alcohol, how does the Sugar Sweetened 
Beverage tax impact health inequalities? 
• Reflecting on health interventions at a population level, does mandatory 
child vaccination raise ethical issues? 
 
Reflection prompts: 
• What is your reflection on…? 
• Do we perceive an issue with…?  
Action orientated prompts: 
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3. Group reflection on health section and the impactibility section in turn 
a. Questions were posed to the group regarding the outcome of the background 









4. Group discussions were had on ethics scenarios 
a. Questions were posed to the group regarding the outcome of the background 








a. During the pilot, group members were posed questions on how their 
reflections from 1-5 would be featured in their work  
b. A member of the group should be made available provide support or facilitate 




• What were some of the thoughts that you had that surprised you in this 
section? 
• Were the questions easy to answer?  If so, why? If not, why? 
• Did you rely on personal or professional experiences to form your 
answers? 
Action orientated prompts: 
• How would we ensure that multiple stakeholders views and 
perspectives are considered in our work? 
• How would we as a group ensure we have a rounded view of …? 
Encompassing all the elements discussed?  
• What action results from this group discussion? 
• How would we as a group expand our understanding further? 
• What would a good outcome of the work look like to you? 
Reflection prompts: 
• Did you feel there were issues in the scenario?  
• Do you think the ethical issue could be navigated? How? 
• What would improve the situation? What would make the situation 
worse? 
• Why is it ok to…? Why is it not ok to…? 
Action orientated prompts: 
• How would we ensure that ethics is considered within our work? 
• How will we ensure that health inequalities are considered within our 
work? 
 
